Compositions, devices, and methods for treatment of overdose and reward-based disorders

Intranasal naltrexone formulations address the limitations of current treatments by providing rapid and effective opioid overdose reversal and reward-based disorder management through optimized nasal delivery systems.

JP2024164155AInactive Publication Date: 2024-11-26AEGIS THERAPEUTICS LLC +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024141729
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-12-20
Filing Date
2024-08-23
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for opioid overdose and reward-based disorders such as alcohol use disorder are limited by the need for needle administration, slow absorption, and the requirement for abstinence before treatment, with existing oral and injectable formulations having low bioavailability and limited efficacy in reducing cravings and consumption.

Method used

Intranasal formulations of naltrexone, potentially with absorption enhancers, administered before or during alcohol consumption to rapidly block opioid receptors and reduce reward-based behaviors, using devices optimized for nasal delivery.

Benefits of technology

Intranasal naltrexone provides rapid absorption and high bioavailability, effectively reducing alcohol cravings and consumption without the need for abstinence, and is applicable for both opioid overdose reversal and reward-based disorder treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164155000001_ABST
    Figure 2024164155000001_ABST
Patent Text Reader

Abstract

To provide simple, fast and compliant means for opioid antagonists such as naltrexone that can reverse opioid overdose and treat alcohol drinking and its operant response.SOLUTION: Drug products adapted for nasal delivery, comprising a device filled with a pharmaceutical composition comprising naltrexone are provided. Formulations and methods of treating alcohol use disorder and related conditions with the drug products are also provided.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Patent Application No. 62 / 782,943, filed December 20, 2018, and U.S. Patent Application No. 16 / 311,944, filed December 20, 2018, the entire disclosures of which are considered part of the disclosure of this application and are incorporated by reference in their entireties in the disclosure of this application. This application also incorporates by reference the disclosures of PCT Publication Nos. WO2017 / 223566 and WO2018 / 089709, as if fully set forth herein.

[0002] FIELD OF THEINVENTION The present invention relates generally to pharmaceutical compositions, and more particularly to intranasal formulations comprising naltrexone and forms thereof, and methods of using intranasal formulations comprising naltrexone and forms thereof in the treatment of conditions and symptoms thereof, such as opioid overdose, and disorders, such as alcohol use disorder, comprising administering an intranasal formulation of the opioid antagonist naltrexone. [Background technology]

[0003] Background information Naltrexone was initially developed to treat opioid dependence due to its effectiveness in blocking the euphoric effects of opioids. Oral naltrexone tablet formulations have been used to treat opioid addiction since 1984. To improve compliance, long-acting depot naltrexone formulations were developed that are administered at monthly or longer intervals. Data from clinical trials have demonstrated that depot formulations are effective in reducing relapse to opioid use. Currently, there is one intramuscular extended release formulation of naltrexone (Vivitrol®) for monthly administration and one oral formulation approved by the FDA. These formulations are intended to maintain a relatively steady state of naltrexone sufficient to consistently prevent naltrexone addiction.

[0004] A related but somewhat different issue, opioid overdose, is a significant public health problem. In 2017, approximately 72,000 people died from drug overdoses. The majority of these, approximately 49,000, involved opioids. More than 19,000 of these deaths involved prescription opioid painkillers other than non-methadone synthetics, nearly 3,300 involved methadone, and approximately 16,000 involved heroin. Nearly 30,000 of these deaths were attributable to fentanyl and related synthetic opioids, which have increased significantly over the years. In summary, in 2016, the number of opioid-related overdose deaths far exceeded the peak number of HIV-related deaths and the peak number of firearm-related deaths, and has increased dramatically over the past nine years. Effective treatments to reverse opioid overdoses remain needed.

[0005] Meanwhile, there remains a need for treatments for "reward-based" disorders that often involve other substances of abuse, such as opioids or alcohol, but also other activities that stimulate the pleasure, reward, and reinforcement centers of the brain, leading to unhealthy and excessive consumption of these substances or preoccupation with these behaviors.

[0006] For example, alcohol can stimulate the brain's reward circuitry, reinforcing uninterrupted drinking. Problematic drinking that becomes severe enough results in a medical diagnosis of alcohol use disorder (AUD). In 2014, approximately 6.8 percent of people aged 18 years and older in the United States (16.3 million adults) had an AUD. This included 10.6 million men and 5.7 million women. Additionally, in 2014, an estimated 679,000 adolescents aged 12–17 years (2.7% of this age group) had an AUD. In 2012, 3.3 million deaths, or 5.9 percent of deaths worldwide (7.6% for men and 4.0% for women), were attributable to alcohol consumption (WHO Global Status Report on Alcohol and Health, 2014).

[0007] To be diagnosed with AUD in the United States, certain criteria must be met as outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM). For example, in the fifth edition of the DSM, any individual who meets two of eleven criteria during the same 12-month period receives a diagnosis of AUD. The severity of AUD - mild, moderate, or severe - is based on the number of criteria met. In Europe, individuals are screened using the Alcohol Use Disorders Identification Test (AUDIT). People with AUD may drink excessively and as a result be a threat to both themselves and others.

[0008] Alcohol abuse is a pattern of drinking that has serious and recurring harmful consequences. Alcoholics may miss important school, work, or family obligations. People with alcoholism (also known as alcohol dependence) have lost firm control over their alcohol use and often are unable to stop drinking once they start. Alcohol dependence is characterized by tolerance (the need to drink more to achieve the same "high") and withdrawal symptoms when drinking is suddenly stopped. Withdrawal symptoms may include nausea, sweating, restlessness, irritability, tremors, hallucinations, and convulsions.

[0009] Problem drinking has multiple causes, with genetic, physiological, psychological, and social factors all playing a role. Not all individuals are equally affected by each cause. In some people with AUD, psychological traits such as impulsivity, low self-esteem, and a need for validation stimulate inappropriate drinking. Genetic factors make some people especially vulnerable to alcohol dependence. AUD may cause physiological changes that make heavy drinking the only way to avoid unpleasant situations, and individuals with AUD may drink alcohol to partially alleviate or avoid withdrawal symptoms.

[0010] Individuals with disorders related to reward-based behavior, such as AUD, can seek counseling and psychological treatment from health professionals, including physicians, nutritionists, psychiatrists, psychologists, and clinical social workers, or by attending 12-step Alcoholics Anonymous meetings. However, access to, and acceptance and success with, such resources may be limited for a variety of reasons.

[0011] There remains a longstanding and significant resistance to the use of pharmacotherapies to treat disorders associated with reward-based behaviors such as AUD, and current evidence indicates that pharmacotherapies are underused in treating AUD. Oral nalmefene is approved in Europe and can be taken by patients while drinking alcohol. However, in the United States, as of January 2015, disulfiram, acamprosate, and oral or extended-release injectable naltrexone are the only drugs approved by the Food and Drug Administration specifically for the treatment of AUD. However, all of these drugs must be taken by inpatients who are able to abstain from alcohol or have completed alcohol withdrawal before treatment begins. Thus, there remains a need for drugs to treat AUD subjects who continue to drink alcohol.

[0012] Non-drug reward-based disorders manifest with similar psychological and behavioral patterns as substance use disorders. In particular, subjects who suffer from addictive behaviors that have negative consequences for a person's physical, mental, social, or economic well-being exhibit cravings, behavioral dyscontrol, tolerance, withdrawal symptoms, and high relapse rates (see, for example, Marks, 1990; Lejoyeux et al, 2000; National Institute on Drug Abuse (NIDA) et al, 2002; Potenza, 2006; and Olsen, 2011). Drug and non-drug rewards also show similar physiological manifestations. For example, functional brain imaging studies in humans have found that gambling (Breiter et al. 2001), shopping (Knutson et al. 2007), orgasm (Komisaruk et al. 2004), playing video games (Koepp et al. 1998; Hoeft et al. 2008), and viewing tasty foods (Wang et al. 2004) activate many of the same brain regions (i.e., the mesocorticolimbic system and extended amygdala) as drugs of abuse (Volkow et al. 2004).

[0013] Intranasal (IN) formulations of naltrexone have the potential to be used to reverse opioid overdose and treat reward-based disorders without the need for needles or sustained release formulations. Although studies have shown that opioid antagonists such as naltrexone administered orally or in injection form can reverse opioid overdose and reduce alcohol drinking and its operant responses, there remains a great need for simple, rapid, and compatible means to treat such conditions. Summary of the Invention

[0014] overview Disclosed herein are intranasal formulations comprising an aqueous solution comprising naltrexone or a pharma- ceutically acceptable salt thereof.

[0015] Also disclosed herein is a method of treating opioid overdose or a reward-based disorder, such as alcohol use disorder (AUD), in a subject, comprising administering to the subject an IN formulation comprising a therapeutically effective amount of naltrexone or a pharma- ceutically acceptable salt thereof.

[0016] Also disclosed herein is a device adapted for nasal delivery of pharmaceutical compositions comprising a therapeutically effective amount of the pharmaceutical formulation disclosed herein to subjects experiencing opioid overdose or having a reward-based disorder, such as alcohol use disorder (AUD).In certain embodiments, the device is pre-primed.In certain embodiments, the device can be primed before use.In certain embodiments, the device is a single-dose device.In certain embodiments, the device is a multi-dose device. [Brief description of the drawings]

[0017] [Figure 1] 1 shows mean naltrexone plasma concentration versus time profiles following administration of Test Product 1, Test Product 2, Test Product 3, and Reference Product, up to 12 hours on a linear scale. [Diagram 2] 1 shows the mean naltrexone plasma concentration versus time profiles following administration of Test Product 1, Test Product 2, Test Product 3, and Reference Product, up to 12 hours on a semi-log scale. [Diagram 3] Mean 6β-naltrexol (the major naltrexone metabolite) plasma concentration versus time profiles following administration of Test Product 1, Test Product 2, Test Product 3, and Reference Product are shown on a linear scale up to 12 hours (ends truncated at 12 hours). [Figure 4] Mean 6β-naltrexol (the major naltrexone metabolite) plasma concentration versus time profiles following administration of Test Product 1, Test Product 2, Test Product 3, and Reference Product are shown on a semi-log scale up to 12 hours (ends truncated at 12 hours). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] Detailed Description The following embodiments further describe the invention disclosed herein.

[0019] The following is provided herein: Aspect 1: An aqueous solution containing about 1 mg to about 4 mg of naltrexone or a pharma- ceutically acceptable salt thereof. 13. An intranasal formulation comprising:

[0020] The following are also provided herein: Aspect 2: An aqueous solution containing about 10 mg / mL to about 40 mg / mL (preferably about 10 mg / mL to about 30 mg / mL) of naltrexone or a pharma- ceutically acceptable salt thereof. in a volume of about 50 to about 250 μL (preferably about 50 to about 150 μL).

[0021] The present disclosure further provides the following aspects: Aspect 3: below: Isotonic agents; Preservatives; Stabilizers; Absorption enhancers; and A sufficient amount of water to achieve a final volume of about 50 to about 250 μL (preferably about 50 to about 150 μL) The formulation of embodiment 1 or embodiment 2, further comprising:

[0022] Aspect 4: below: about 1 mg to about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof; about 0.1 mg to about 1.2 mg of an isotonic agent; from about 0.001 mg to about 0.1 mg of a preservative; about 0.1 mg to about 0.5 mg of a stabilizer; about 0.05 mg to about 2.5 mg of an absorption enhancer; and A sufficient amount of water to achieve a final volume of about 50 to about 250 μL (preferably about 50 to about 150 μL) 4. The formulation of embodiment 3, comprising:

[0023] Aspect 5: below: about 1% to about 3% naltrexone or a pharma- ceutically acceptable salt thereof; about 0.1% to about 1.2% isotonic agent; About 0.001% to about 0.1% preservatives; about 0.1% to about 0.5% of a stabilizer; Approximately 0.05% mg to approximately 2.5% of absorption enhancer 4. The formulation of embodiment 3, comprising:

[0024] Aspect 6: The isotonic agent is NaCl, The preservative is benzalkonium chloride. The stabilizer is edetate disodium, The absorption enhancer is an alkyl saccharide; The formulation of embodiment 4 or embodiment 5.

[0025] Aspect 7: The formulation of embodiment 6, wherein the alkyl saccharide is dodecyl maltoside.

[0026] Aspect 8: below: about 1 mg to about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof; About 0.1 mg to about 1.2 mg NaCl; about 0.001 mg to about 0.1 mg of benzalkonium chloride; about 0.15 mg to about 0.5 mg of disodium edetate; about 0.05 mg to about 2.5 mg of dodecyl maltoside; and A sufficient amount of water to achieve a final volume of about 50 to about 250 μL (preferably about 50 to about 150 μL) 8. The formulation of embodiment 7, comprising:

[0027] Aspect 9: The formulation of embodiment 8, comprising about 0.1 mg to about 0.5 mg of dodecyl maltoside.

[0028] Aspect 10: 10. The formulation of embodiment 9, comprising about 0.25 mg of dodecyl maltoside.

[0029] Aspect 11: The formulation of embodiment 8, comprising about 0.2 mg and about 0.3 mg of edetate disodium.

[0030] Aspect 12: below: about 1 mg to about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof; about 0.3 mg to about 0.7 mg NaCl; Approximately 0.02 mg of benzalkonium chloride; Approximately 0.3 mg of edetate disodium; Approximately 0.25 mg of dodecyl maltoside; and A sufficient amount of water to achieve a final volume of about 50 to about 250 μL (preferably about 50 to about 150 μL) 10. The formulation of embodiment 9, comprising:

[0031] Aspect 13: The formulation of embodiment 10, wherein the amount of water is sufficient to achieve a final volume of about 80 to about 120 μL.

[0032] Aspect 14: The formulation of embodiment 11, wherein the amount of water is sufficient to achieve a final volume of about 100 μL.

[0033] Aspect 15: below: about 1% to about 3% naltrexone or a pharma- ceutically acceptable salt thereof; About 0.1% to about 1.2% NaCl; about 0.001% to about 0.1% benzalkonium chloride; about 0.15% to about 0.5% disodium edetate; about 0.05% to about 2.5% dodecyl maltoside; and water 8. The formulation of embodiment 7, comprising:

[0034] Aspect 16: 16. The formulation of embodiment 15, comprising about 0.1% to about 0.5% dodecyl maltoside.

[0035] Aspect 17: 17. The formulation of embodiment 16, comprising about 0.25% dodecyl maltoside.

[0036] Aspect 18: The formulation of embodiment 15, comprising about 0.2% and about 0.3% edetate disodium.

[0037] Aspect 19: below: about 1% to about 3% naltrexone or a pharma- ceutically acceptable salt thereof; About 0.3% to about 0.7% NaCl; about 0.02% benzalkonium chloride; Disodium edetate, approximately 0.3%; about 0.25% dodecyl maltoside; and water 20. The formulation of embodiment 17, comprising:

[0038] Aspect 20: The formulation of embodiment 19, wherein the amount of water is sufficient to achieve a final volume of about 50 to about 150 μL.

[0039] Aspect 21: 21. The formulation of embodiment 20, wherein the amount of water is sufficient to achieve a final volume of about 100 μL.

[0040] Aspect 22: 22. The formulation of any one of aspects 1-21, wherein the naltrexone is naltrexone hydrochloride.

[0041] Aspect 23: 23. The formulation of embodiment 22, comprising about 1.2 mg, about 1.6 mg, about 2.0 mg, or about 3.0 mg of naltrexone or an equivalent amount of naltrexone hydrochloride.

[0042] The following are also provided herein: Aspect 24: 1. A method of treating an opioid overdose or a reward-based disorder in a subject, comprising: An aqueous solution containing about 1 mg to about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof. administering to a subject an intranasal formulation comprising A method comprising:

[0043] The following are also provided herein: Aspect 25: 1. A method of treating an opioid overdose or a reward-based disorder in a subject, comprising: An aqueous solution containing about 1 mg to about 4 mg of naltrexone or a pharma- ceutically acceptable salt thereof. administering to the subject a first intranasal formulation comprising: An aqueous solution containing about 1 mg to about 4 mg of naltrexone or a pharma- ceutically acceptable salt thereof. administering a second intranasal formulation comprising A method comprising:

[0044] The following are also provided herein: Aspect 26: 1. A method of treating an opioid overdose or a reward-based disorder in a subject, comprising: An aqueous solution containing about 10 mg / mL to about 40 mg / mL (preferably about 10 mg / mL to about 30 mg / mL) of naltrexone or a pharma- ceutically acceptable salt thereof. in a volume of about 50 to about 250 μL (preferably about 50 to about 150 μL), A method comprising:

[0045] The following are also provided herein: Aspect 27: 1. A method of treating an opioid overdose or a reward-based disorder in a subject, comprising: An aqueous solution containing about 10 mg / mL to about 40 mg / mL of naltrexone or a pharma- ceutically acceptable salt thereof. administering to the subject a first intranasal formulation comprising in a volume of about 50 to about 250 ul; and An aqueous solution containing about 10 mg / mL to about 40 mg / mL of naltrexone or a pharma- ceutically acceptable salt thereof. in a volume of about 50 to about 250 μL. A method comprising:

[0046] Aspect 28: The method of embodiment 25 or embodiment 27, wherein the second intranasal formulation is administered about 1 hour to about 3 hours after the first intranasal formulation is administered.

[0047] Aspect 29: Intranasal formulations include: Isotonic agents; Preservatives; Stabilizers; Absorption enhancers; and A sufficient amount of water to achieve a final volume of about 50 to about 250 μL (preferably about 50 to about 150 μL) The method according to any one of aspects 24 to 28, further comprising:

[0048] Aspect 30: The intranasal formulation about 1 mg to about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof; about 0.1 mg to about 1.2 mg of an isotonic agent; from about 0.001 mg to about 0.1 mg of a preservative; about 0.1 mg to about 0.5 mg of a stabilizer; about 0.05 mg to about 2.5 mg of an absorption enhancer; and A sufficient amount of water to achieve a final volume of about 50 to about 250 μL (preferably about 50 to about 150 μL) 30. The method of embodiment 29, comprising:

[0049] Aspect 31: Intranasal formulations include: about 1% to about 3% naltrexone or a pharma- ceutically acceptable salt thereof; about 0.1% to about 1.2% isotonic agent; About 0.001% to about 0.1% preservatives; about 0.1% to about 0.5% of a stabilizer; Approximately 0.05% mg to approximately 2.5% of absorption enhancer 30. The method of embodiment 29, comprising:

[0050] Aspect 32: The isotonic agent is NaCl, The preservative is benzalkonium chloride. The stabilizer is edetate disodium, The absorption enhancer is an alkyl saccharide; The method of embodiment 30 or embodiment 28.

[0051] Aspect 33: The method of embodiment 32, wherein the alkyl saccharide is dodecyl maltoside.

[0052] Aspect 34: Intranasal formulations include: about 1 mg to about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof; About 0.1 mg to about 1.2 mg NaCl; about 0.001 mg to about 0.1 mg of benzalkonium chloride; about 0.15 mg to about 0.5 mg of disodium edetate; about 0.05 mg to about 2.5 mg of dodecyl maltoside; and A sufficient amount of water to achieve a final volume of about 50 to about 250 μL (preferably about 50 to about 150 μL) 34. The method of embodiment 33, comprising:

[0053] Aspect 35: The method of embodiment 34, wherein the intranasal formulation comprises from about 0.1 mg to about 0.5 mg of dodecyl maltoside.

[0054] Aspect 36: The method of embodiment 35, wherein the intranasal formulation comprises about 0.25 mg of dodecyl maltoside.

[0055] Aspect 37: The method of embodiment 34, wherein the intranasal formulation comprises about 0.2 mg to about 0.3 mg of edetate disodium.

[0056] Aspect 38: The intranasal formulation about 1 mg to about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof; about 0.3 mg to about 0.7 mg NaCl; Approximately 0.02 mg of benzalkonium chloride; Approximately 0.3 mg of edetate disodium; Approximately 0.25 mg of dodecyl maltoside; and A sufficient amount of water to achieve a final volume of about 50 to about 250 μL (preferably about 50 to about 150 μL) 37. The method of embodiment 36, comprising:

[0057] Aspect 39: The method of embodiment 38, wherein the amount of water is sufficient to achieve a final volume of about 50 to about 150 μL.

[0058] Aspect 40: 40. The method of embodiment 39, wherein the amount of water is sufficient to achieve a final volume of about 100 μL.

[0059] Aspect 41: below: about 1% to about 3% naltrexone or a pharma- ceutically acceptable salt thereof; About 0.1% to about 1.2% NaCl; about 0.001% to about 0.1% benzalkonium chloride; about 0.1% to about 0.5% disodium edetate; about 0.05% to about 2.5% dodecyl maltoside; and water 34. The method of embodiment 33, comprising:

[0060] Aspect 42: The method of embodiment 41, wherein the intranasal formulation comprises about 0.1% to about 0.5% dodecyl maltoside.

[0061] Aspect 43: The method of embodiment 42, wherein the intranasal formulation comprises about 0.25% dodecyl maltoside.

[0062] Aspect 44: The method of embodiment 41, wherein the intranasal formulation comprises about 0.2% to about 0.3% edetate disodium.

[0063] Aspect 45: Intranasal formulations include: about 1% to about 3% naltrexone or a pharma- ceutically acceptable salt thereof; About 0.3% to about 0.7% NaCl; about 0.02% benzalkonium chloride; Disodium edetate, approximately 0.3%; about 0.25% dodecyl maltoside; and water 44. The method of embodiment 43, comprising:

[0064] Aspect 46: The method of embodiment 45, wherein the amount of water is sufficient to achieve a final volume of about 50 to about 150 μL.

[0065] Aspect 47: 47. The method of embodiment 46, wherein the amount of water is sufficient to achieve a final volume of about 100 μL.

[0066] Aspect 48: The method of any one of aspects 24 to 47, wherein the naltrexone is naltrexone hydrochloride.

[0067] Aspect 49: The method of embodiment 48, wherein the intranasal formulation comprises about 1.2 mg, about 1.6 mg, about 2.0 mg, or about 3.0 mg of naltrexone or an equivalent amount of naltrexone hydrochloride.

[0068] Aspect 50: 50. The method of any one of aspects 24 to 49, for treating opioid overdose.

[0069] Aspect 51: 50. The method according to any one of embodiments 24 to 49, for treating a reward-based disorder.

[0070] Aspect 52: The method of embodiment 48, wherein the reward-based disorder is a substance use disorder.

[0071] Aspect 53: The method of embodiment 48, wherein the substance use disorder is alcohol use disorder.

[0072] Aspect 54: The method of embodiment 53, wherein the intranasal formulation comprising naltrexone is administered prior to alcohol consumption.

[0073] Aspect 55: The method of embodiment 54, wherein the intranasal formulation comprising naltrexone is administered about 1 to 2 hours prior to alcohol consumption.

[0074] Aspect 56: The method of embodiment 54, wherein the intranasal formulation comprising naltrexone is administered about 0.5 to about 1 hour prior to alcohol consumption.

[0075] Aspect 57: 55. The method of embodiment 54, wherein the intranasal formulation comprising naltrexone is administered about 10 to about 30 minutes prior to alcohol consumption.

[0076] Aspect 58: The method of embodiment 54, wherein the intranasal formulation comprising naltrexone is administered about 5 to about 10 minutes prior to alcohol consumption.

[0077] Aspect 59: The method of embodiment 53, wherein the intranasal formulation comprising naltrexone is administered simultaneously with alcohol intake.

[0078] Aspect 57: The method of embodiment 53, wherein the intranasal formulation comprising naltrexone is administered within 0.5 hours after the start of alcohol ingestion.

[0079] Aspect 58: The method of any of aspects 24-57, wherein an intranasal formulation comprising naltrexone is administered to the subject from 1 to 4 times daily.

[0080] Aspect 59: The method of embodiment 58, wherein the intranasal formulation comprising naltrexone is administered at a dose of about 1.2 mg, about 1.6 mg, about 2 mg, or about 3 mg throughout the day as needed by the subject.

[0081] Aspect 60: The method of embodiment 58, wherein an intranasal formulation comprising naltrexone is administered as a first dose of about 1.2 mg, about 1.6 mg, about 2 mg, or about 3 mg in the morning and a subsequent dose of about 1.2 mg, about 1.6 mg, about 2 mg, or about 3 mg as needed prior to alcohol consumption.

[0082] The following are also provided herein: Aspect 61: 24. The method of claim 1, further comprising administering to said patient a dose of said intranasal formulation comprising: A multi-dose device adapted for nasal delivery of pharmaceutical formulations to subjects experiencing an opioid overdose or having a reward-based disorder.

[0083] Aspect 62: The device of embodiment 61, wherein each dose delivers about 0.05 to about 0.2 mL (preferably about 0.05 to about 0.15 mL) of the formulation to the subject.

[0084] Aspect 63: 63. The device of embodiment 62, wherein each dose delivers about 0.1 mL of the formulation to the subject.

[0085] The following are also provided herein: Aspect 64: "Containing about 1 mg to about 4 mg of naltrexone or a pharma- ceutically acceptable salt thereof" means that the amount contained is about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof; or If the method describes "containing about 10 mg / mL to about 40 mg / mL (preferably about 10 mg / mL to about 30 mg / mL) of naltrexone or a pharma- ceutically acceptable salt thereof," the concentration contained is about 30 mg / mL of naltrexone or a pharma- ceutically acceptable salt thereof. A formulation, method, or device according to any one of the preceding aspects.

[0086] Aspect 64: Also provided is a formulation selected from those described in the Examples disclosed herein.

[0087] Any of the above aspects, and any one or more combinations of these aspects may be combined, unless such combinations are mutually exclusive, are also provided.

[0088] definition When used herein, the following terms have the meanings indicated.

[0089] When a range of values ​​is disclosed, unless otherwise specified, the notation is intended to include the number itself and the range between the numbers. The range may be integer or continuous, between and including the endpoints. As an example, doses are expressed in integer units, so the range "2-6 doses" is intended to include 2, 3, 4, 5, and 6 doses. Compare, as an example, the range "1-3 μM (micromolar)" is intended to include 1 μM, 3 μM, and any number of significant figures therebetween (e.g., 1.255 μM, 2.1 μM, 2.9999 μM, etc.).

[0090] The term "about" as used herein is intended to modify the numerical value it modifies by indicating such value as being variable within a range. In the absence of a specific range being described, such as an error range or standard deviation for a mean value given in a graph or table of data, the term "about" should be understood to mean the greater of the range that includes the stated value, the range that is included by rounding the number up or down to take into account significant digits, and the range that includes the stated value ±20%.

[0091] The term "absorption enhancer" as used herein refers to a functional excipient included in a formulation to improve the absorption of a pharmacologically active drug. The term generally refers to an agent that functions to increase absorption by enhancing membrane penetration rather than increasing solubility. Thus, such agents are sometimes also referred to as penetration enhancers. Examples of absorption enhancers include aprotinin, benzalkonium chloride, benzyl alcohol, capric acid, ceramide, cetylpyridinium chloride, chitosan, cyclodextrin, deoxycholic acid, decanoyl carnitine, dodecyl maltoside, EDTA, glycocholic acid, glycodeoxycholic acid, glycofurol, glycosylated sphingosine, glycyrrhetinic acid, 2-hydroxypropyl-β-cyclodextrin, laureth-9, lauric acid, lauroyl carnitine, sodium lauryl sulfate, lysophosphatidylcholine, menthol, poloxamer 407 or F68, poly-L-arginine, polyoxyethylene-9-lauryl ether, polysorbate 80, propylene glycol, quillaja saponin, salicylic acid, sodium salt, β-sitosterol-β-D-glucoside, sucrose coconutate, These include glycerol, taurocholic acid, taurodeoxycholic acid, taurodihydrofusidic acid, and tetradecylmaltoside. Alkyl saccharides (e.g., nonionic alkyl saccharide surfactants, e.g., alkyl glycosides linked to a sugar moiety by glycosidic bonds, and sucrose esters of fatty acids consisting of aliphatic hydrocarbon chains linked to a sugar moiety by ester bonds), cyclodextrins (cyclic oligosaccharides composed of six or more monosaccharide units with a central cavity that form inclusion bodies with hydrophobic molecules. They have been used primarily to increase drug solubility and dissolution, and to enhance low molecular weight drug absorption), chitosan (a linear cationic polysaccharide produced from the deacetylation of chitin), and bile salts and their derivatives (e.g., sodium glycocholate, sodium taurocholate, and sodium taurodihydrofusidic acid) tend to be among the most tolerated absorption enhancers.See, e.g., Aungst, AAPS Journal 14(1):10-8, 2011; Maggio, J. Excipients and Food Chem. 5(2):100-12, 2014.

[0092] As used herein, the term "addiction" refers to a medical condition characterized by a compulsive preoccupation with a rewarding stimulus despite harmful consequences. As used herein, the term "addictive behavior" refers to a behavior that provides both reward and reinforcement.

[0093] The term "agonist" as used herein refers to a moiety that interacts with and activates a receptor, thereby initiating a physiological or pharmacological response specific to that receptor. The term "antagonist" as used herein refers to a moiety that competitively binds to the same site of a receptor as an agonist (e.g., an endogenous ligand), but does not activate the intracellular response initiated by an activated form of the receptor, thereby being able to inhibit the intracellular response by an agonist or partial agonist. An antagonist does not reduce the baseline intracellular response in the absence of an agonist or partial agonist. The term "inverse agonist" refers to a moiety that binds to an endogenous or constitutively activated form of a receptor, and inhibits the baseline intracellular response initiated by an activated form of the receptor below the normal basal activity level observed in the absence of an agonist or partial agonist.

[0094] The term "alcohol use disorder" is defined in the US by the criteria set out in the Diagnostic and Statistical Manual of Mental Disorders (DSM, latest revision, now DSM-V) or by similar criteria set out in corresponding widely accepted standard texts, such as the World Health Organization's ICD (International Statistical Classification of Diseases and Related Health Problems, latest revision, now ICD-10). Related terms and disorders include "alcohol abuse" and "alcohol dependence" (as used in DSM-IV), "alcohol harmful use" and "alcohol dependence syndrome" (as used in ICD-10), and alcoholism.

[0095] As used herein, the term "antimicrobial preservative" refers to a pharma- ceutically acceptable excipient with antimicrobial properties that is added to a pharmaceutical composition to maintain microbiological stability. The compound acts as both a preservative and a stabilizer.

[0096] As used herein, the terms "disease", "disorder", "syndrome", and "condition" (such as a medical condition) are intended to be largely synonymous and are used interchangeably, as all of these reflect an abnormal condition of the human or animal body, or one of its parts, that impairs normal function, is typically manifested by well-characterized signs and symptoms, and reduces the lifespan or quality of life of the human or animal.

[0097] The term "pharmaceutical composition" is used interchangeably herein with the term "pharmaceutical formulation" or simply "formulation" and refers to a combination of an active pharmaceutical ingredient (i.e., a drug substance) and at least one pharma- ceutically acceptable excipient or carrier.

[0098] As used herein, the term "equivalent" refers to an amount by weight of the opioid antagonist naltrexone and its pharma- ceutically acceptable salts that is equimolar to the specified weight of naltrexone hydrochloride.

[0099] The term "excipient" as used herein refers to a natural or synthetic substance that is formulated with an active ingredient of a drug therapy and included for the purpose of providing long-term stabilization, bulking up a solid formulation, or imparting a therapeutic enhancement to the active ingredient in the final dosage form, such as facilitating drug absorption, reducing viscosity, or increasing solubility.

[0100] As used herein, the term "therapeutically effective dose" refers to a dose effective to treat a disease, reduce one or more observable symptoms of a disease, or delay the onset or progression of, or alleviate, a more serious condition that often follows the condition currently experienced by the patient. A therapeutically effective dose may eliminate all symptoms of a disease, but need not necessarily completely eliminate all symptoms of a disease.

[0101] The terms "in need of treatment" and "in need of" when referring to treatment are used interchangeably and refer to the judgment made by a caregiver (e.g., physician, nurse, nurse practitioner) that the subject will benefit from treatment.

[0102] As used herein, two embodiments are mutually exclusive when one is defined as being different from the other.For example, an embodiment in which the amount of naltrexone hydrochloride is specified as 3mg is mutually exclusive with an embodiment in which the amount of naltrexone hydrochloride is specified as 2mg.However, an embodiment in which the amount of naltrexone hydrochloride is specified as 4mg is not mutually exclusive with an embodiment in which less than about 10% of the pharmaceutical composition leaves the nasal cavity and is discharged via drainage into the nasopharynx or outside.

[0103] As used herein, the term "naloxone" has the following structure: TIFF2024164155000002.tif42128 or a pharma- ceutically acceptable salt, hydrate, or solvate thereof. Naloxone's CAS Registry Number is 465-65-6. Other names for naloxone include 17-allyl-4,5a-epoxy-3,14-dihydroxymorphinan-6-one; (-)-17-allyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one; 4,5a-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; and (-)-12-allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one. Naloxone hydrochloride can be anhydrous (CAS Registry Number 357-08-4) or it can form a dihydrate (CAS Registry Number 51481-60-8). It is sold under a variety of trade names, including Narcan®, Nalone®, Nalossone®, Naloxona®, Naloxonum®, Narcanti®, and Narcon®.

[0104] As used herein, the term "naltrexone" has the following structure: TIFF2024164155000003.tif41128 or a pharma- ceutically acceptable salt, hydrate, or solvate thereof. Naltrexone's CAS Registry Number is 16590-41-3. Other names for naltrexone include 17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one; (5α)-17-(cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-one; and (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one. The term "naltrexone" includes "naltrexone hydrochloride." Naltrexone hydrochloride (CAS Registry Number 16676-29-2) is sold under the trade names Antaxone®, Depade®, Nalorex®, Revia®, Trexan®, Vivitrex®, and Vivitrol®.

[0105] As used herein, the term "methylnaltrexone" has the following structure: TIFF2024164155000004.tif46128, which refers to a pharma- ceutically acceptable salt containing the cation (5α)-17-(cyclopropylmethyl)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinanium-17-ium-6-one, a compound of formula - is a pharma- ceutically acceptable anion. Methylnaltrexone bromide (CAS Registry Number 75232-52-7) is sold under the trade name Relistol®.

[0106] As used herein, the term "nalmefene" has the following structure: Refers to 17-cyclopropylmethyl-4,5α-epoxy-6-methylenemorphinan-3,14-diol, a compound of TIFF2024164155000005.tif43128. Nalmefene hydrochloride (CAS Registry Number 58895-64-0) is sold under the trade names Nalmetrene®, Cervene®, Revex®, Arthrene®, and Incystene®.

[0107] As used herein, the term "nostril" is synonymous with "nostril."

[0108] The term "opioid antagonist" includes naloxone, methylnaltrexone, and nalmefene, as well as naltrexone and its pharma- ceutically acceptable salts. In certain embodiments, the opioid antagonist is naltrexone hydrochloride. In certain embodiments, the opioid antagonist is naloxone. In certain embodiments, the opioid antagonist is methylnaltrexone bromide. In certain embodiments, intranasal administration is accomplished using a device described herein.

[0109] As used herein, the term "pharmaceutical composition" refers to a composition comprising at least one active ingredient, including, but not limited to, salts, solvates, and hydrates of the opioid antagonist naltrexone, whereby said composition is intended for use in a mammal, such as, but not limited to, a human, to obtain a specified beneficial outcome.

[0110] As used herein, the term "reinforcing stimuli" refers to stimuli that increase the likelihood of repeating the behavior with which they are paired.

[0111] As used herein, the term "rewarding stimulus" refers to a stimulus that a subject's brain interprets as inherently good or challenging. Typically, rewarding stimuli result in the release of dopamine in the subject's brain.

[0112] As used herein, "reward-based disorder" refers to a disorder related to reward-based behavior, in which the user continues to be preoccupied with rewarding stimuli and / or becomes addicted to rewarding stimuli despite adverse consequences.Reward-based disorders include substance use disorders, such as alcohol use disorders, and addictions, and activity engagement disorders, such as gambling disorder (compulsive gambling), eating disorders (binge eating, bulimia nervosa), kleptomania, pyromania, etc.

[0113] As used herein, the term "subject" is intended to be synonymous with "patient" and refers to any mammal, preferably a human, having a condition that is likely to benefit from treatment with a therapeutically effective amount of the opioid antagonist naltrexone, or a salt thereof.

[0114] The term "substance use disorder" is defined in the US by the criteria set out in the Diagnostic and Statistical Manual of Mental Disorders (DSM, latest revision, now DSM-V) or by similar criteria set out in corresponding widely accepted standard texts, e.g., the World Health Organization's ICD (International Statistical Classification of Diseases and Related Health Problems, latest revision, now ICD-10). Related terms and disorders include "substance abuse" and "substance dependence" (as used in DSM-IV). Substance use disorder occurs when repeated use of alcohol and / or drugs causes clinically or functionally significant impairment, e.g., health problems, physical disability, or failure to fulfill significant obligations at work, school, or home. According to DSM-5, the diagnosis of substance use disorder is based on evidence of dysfunctional control, social impairment, risky use, and pharmacological criteria. Substances that can be the focus of substance use disorders include substances of abuse such as opioids, alcohol, tobacco, cannabinoids, stimulants such as cocaine and amphetamines, depressants such as benzodiazepines, hallucinogens, inhalants, etc. Alcohol use disorder is a substance use disorder. Substance use disorders are sometimes considered "reward-based disorders".

[0115] The term "tonicity agent" as used herein refers to a compound that modifies the osmolality of a formulation, e.g., makes it isotonic. Tonicity agents include dextrose, lactose, sodium chloride, calcium chloride, magnesium chloride, sorbitol, sucrose, mannitol, trehalose, raffinose, polyethylene glycol, hydroxyethyl starch, glycine, and the like.

[0116] As used herein, "treat," "treatment," and the like refer to ameliorating a disorder so as to reduce or eliminate one or more of the causes, progression, severity, or symptoms of a disorder in a subject, or to otherwise beneficially alter a disease.

[0117] As used herein, the term "AUC" refers to the area under the drug plasma concentration-time curve. 0-t The term "AUC" refers to the area under the drug plasma concentration-time curve from t=0 to the last measurable concentration. 0-∞ " or "AUC 0-inf " refers to the area under the drug plasma concentration-time curve extrapolated to ∞ (infinity).

[0118] As used herein, the term "bioavailability (F)" refers to the fraction of a drug dose that is absorbed from the site of administration and reaches the systemic circulation in an unchanged form. As used herein, the term "absolute bioavailability" is used when the fraction of a drug absorbed is related to its IV bioavailability, which can be expressed by the following formula: This can be calculated using TIFF2024164155000006.tif12128.

[0119] Relative bioavailability (F rel ) is used to compare two different extravascular routes of drug administration and is expressed as follows: This can be calculated using TIFF2024164155000007.tif12128.

[0120] As used herein, the term "clearance (CL)" refers to the rate at which a drug is eliminated divided by the plasma concentration of the drug, and represents the volume of plasma from which the drug is completely removed per unit time. CL is the product of the elimination rate constant (λ) and the volume of distribution (V d ) multiplied by "V d " is the fluid volume required to contain the amount of drug present in the body at the same concentration as in plasma. As used herein, the term "apparent clearance (CL / F)" refers to the clearance without taking into account the bioavailability of the drug. It is the ratio of dose over AUC.

[0121] As used herein, "C max " refers to the maximum observed plasma concentration.

[0122] As used herein, "t 1 / 2 The term "half-life" or "half-life" refers to the time required for half of a drug to be eliminated from the body or the time required for the drug concentration to decrease by half.

[0123] As used herein, the term "coefficient of variation (CV)" refers to the ratio of the sample standard deviation to the sample mean. "Coefficient of variation (CV)" is often expressed as a percentage.

[0124] As used herein, the term "confidence interval" refers to a range of values ​​that contains, with a specified percentage probability, the true mean value of a parameter.

[0125] As used herein, the term "elimination rate constant (λ)" refers to the rate, expressed as a fraction, at which a drug is eliminated from the body. This rate is first order, constant, and independent of drug concentration in the body. λ is the slope of the plasma concentration-time line (on a logarithmic y scale). As used herein, "λ" refers to the rate at which a drug is eliminated from the body, expressed as a fraction. This rate is first order, constant, and independent of drug concentration in the body. λ is the slope of the plasma concentration-time line (on a logarithmic y scale). zThe term "terminal phase" refers to the terminal elimination rate constant. The "terminal phase" of a drug plasma concentration-time curve is a straight line when plotted on a semi-log graph. The terminal phase is often also called the "elimination phase" because the primary mechanism that reduces drug concentrations during the terminal phase is drug elimination from the body. The terminal elimination phase is characterized by the relative proportions of drug in the plasma and in the peripheral volume of distribution remaining constant. During this "terminal phase", the drug returns to plasma from the rapid and slow volumes of distribution and is permanently removed from plasma by metabolism or renal excretion.

[0126] Opioid antagonists Opioid receptor antagonists are a well-recognized class of chemicals. Opioid receptor antagonists are well-described in the scientific and patent literature. Naltrexone and its active metabolite 6β-naltrexol are opioid antagonists at μ-opioid receptors (MOR), κ-opioid receptors (KOR), and δ-opioid receptors (DOR), with no agonist properties. Naltrexone works by reversibly blocking opioid receptors, thereby attenuating the effects of opioids. Although its mechanism of action in alcoholism is not fully understood, and without being limited by theory, naltrexone likely modulates the dopaminergic mesolimbic pathway, which is believed to be the primary reward center associated with addiction, one of the primary centers of risk-reward analysis in the brain, and the tertiary pleasure center, which all major drugs of abuse are believed to activate. Its mechanism of action may be antagonism to endogenous opiates, such as tetrahydropapaveroline, the production of which is increased in the presence of alcohol.

[0127] Naltrexone is commercially available as the hydrochloride salt. Naltrexone hydrochloride (17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one) is used to block the euphoric effects in the treatment of patients with opioid addiction. It significantly blocks physical dependence on intravenously administered opioids and stimulates withdrawal symptoms from opioid addiction, but patients do not develop tolerance or dependence to naltrexone. Naltrexone is also effective in the treatment of alcoholism to reduce alcohol craving, especially when combined with psychosocial therapy.

[0128] When naltrexone is administered intranasally rather than orally, bioavailability is considerably higher. Although naltrexone is almost completely absorbed from the gastrointestinal tract when administered orally, it undergoes rapid and extensive first-pass metabolism to 6-β-naltrexol. As a result, the amount of naltrexone that reaches the systemic circulation is limited. The oral bioavailability of naltrexone has been reported to be as low as 5%. Gonzalez and Brogden, Drugs 35:192-213, 1988. From the studies presented herein, it was found that the oral bioavailability of naltrexone is similarly low, about 9%.

[0129] Provided herein is a method of treatment using intranasal delivery of a pharmaceutical composition to a patient, comprising a therapeutically effective amount of the opioid antagonist naltrexone. In certain embodiments, the therapeutically effective amount per dose corresponds to about 1 to about 4 mg of naltrexone hydrochloride. In certain embodiments, the therapeutically effective amount corresponds to about 1 to about 3 mg of naltrexone hydrochloride. In certain embodiments, the therapeutically effective amount per dose is equivalent to about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, about 2.0, about 2.1, about 2.2, about 2.3, about 2.4, about 2.5, about 2.6, about 2.7, about 2.8, about 2.9, about 3.0, about 3.1, about 3.2, about 3.3, about 3.4, about 3.5, about 3.6, about 3.7, about 3.8, about 3.9 or about 4.0mg of naltrexone hydrochloride.In certain embodiments, the therapeutically effective amount per dose is equivalent to about 1.2mg of naltrexone hydrochloride.In certain embodiments, the therapeutically effective amount per dose is equivalent to about 1.6mg of naltrexone hydrochloride. In certain embodiments, the therapeutically effective amount per dose is equivalent to about 2.0mg naltrexone hydrochloride.In certain embodiments, the therapeutically effective amount per dose is equivalent to about 3.0mg naltrexone hydrochloride.Multiple doses may be taken consecutively to achieve therapeutic efficacy.In certain embodiments, the opioid antagonist is anhydrous naltrexone hydrochloride.

[0130] Although many of the aspects of the pharmaceutical compositions described herein are described and exemplified with naltrexone, other opioid antagonists can be adapted for nasal delivery based on the disclosure herein.In fact, it should be readily apparent to those skilled in the art from the disclosure herein that the devices and pharmaceutical compositions described herein may be suitable for other opioid antagonists.The opioid receptor antagonists described herein include μ-opioid, κ-opioid, and δ-opioid receptor antagonists.Examples of useful opioid receptor antagonists include naltrexone, naloxone, methylnaltrexone, and nalmefene.Other useful opioid receptor antagonists are known in the art (e.g., U.S. Pat. No. 4,987,136).

[0131] Pharmaceutical preparations Also provided is a pharmaceutical composition comprising the opioid antagonist naltrexone. In certain embodiments, the pharmaceutical composition comprises the opioid antagonist naltrexone and a pharma- ceutically acceptable carrier. The carrier must be "acceptable" in the sense of being compatible with the other components of the formulation and not unduly harmful to the recipient thereof. Some embodiments of the present invention include a method of producing a pharmaceutical composition, comprising the step of mixing the opioid antagonist naltrexone with a pharma- ceutically acceptable carrier. The pharmaceutical composition is applied directly to the nasal cavity using a device described herein. In the case of a spray, this can be accomplished, for example, by a metering atomizing spray pump.

[0132] Liquid preparations include solutions, suspensions, and emulsions, such as water or water-propylene glycol solutions. Additional ingredients in liquid preparations include antimicrobial preservatives, such as benzalkonium chloride, methylparaben, sodium benzoate, benzoic acid, phenylethyl alcohol, and the like, and mixtures thereof; surfactants, such as polysorbate 80NF, polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene (4) sorbitan monolaurate, polyoxyethylene 20 sorbitan monopalmitate, polyoxyethylene 20 sorbitan monostearate, polyoxyethylene (4) sorbitan monostearate, polyoxyethylene 20 sorbitan tristearate, polyoxyethylene (5) sorbitan monooleate, polyoxyethylene 20 sorbitan trioleate, polyoxyethylene 20 sorbitan monoisostearate ... sorbitan stearate, sorbitan monooleate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan trilaurate, sorbitan trioleate, sorbitan tristearate, and the like, and mixtures thereof; tonicity agents, such as dextrose, lactose, sodium chloride, calcium chloride, magnesium chloride, sorbitol, sucrose, mannitol, trehalose, raffinose, polyethylene glycol, hydroxyethyl starch, glycine, and the like, and mixtures thereof; and suspending agents, such as microcrystalline cellulose, sodium carboxymethylcellulose NF, polyacrylic acid, magnesium aluminum silicate, xanthan gum, and the like, and mixtures thereof.

[0133] Ideally, when an opioid antagonist is administered intranasally prior to alcohol ingestion to treat AUD, the opioid antagonist is rapidly absorbed, i.e., within about 15 to about 30 minutes, and / or has a time to maximum plasma concentration (T) of about 25 to about 40 minutes. max For example, in certain embodiments, the opioid antagonist is absorbed within the first 15 minutes after administration and results in a time to maximum plasma concentration (T max) is less than 25 minutes. Alternatively, opioid antagonists are absorbed within the first 30 minutes after administration, and T max is less than 40 minutes.

[0134] The use of absorption enhancers, such as alkyl saccharides (also referred to herein as alkyl glycosides), cyclodextrins, and chitosan, can increase the rate at which naltrexone is absorbed, thus increasing the T max Such absorption enhancers typically work by affecting the two main mechanisms of nasal absorption: paracellular transport through openings in tight junctions between cells, and transcellular transport or transcytosis through cells via vesicular carriers.

[0135] In various aspects, the alkyl glycosides of the present invention are alkyl glycosides, such as octyl-, nonyl-, decyl-, undecyl-, dodecyl-, tridecyl-, tetradecyl-, pentadecyl-, hexadecyl-, heptadecyl-, and octadecyl-α- or β-D-maltosides, -glucosides, or -sucrosides; alkyl thiomaltosides, such as heptyl, octyl, dodecyl-, tridecyl-, and tetradecyl-β-D-thiomaltosides; alkyl thioglucosides, such as heptyl- or octyl 1-thio α-glucosides, - or β-D-glucopyranosides; alkylthiosucrose; alkylmaltotriosides; long chain aliphatic carbonate amides of sucrose β-amino-alkyl ethers; derivatives of isomaltamine and palatinose linked to the alkyl chain by an amide bond; derivatives of isomaltamine linked to the alkyl chain by a urea bond; long chain aliphatic carbonate ureides of sucrose β-amino-alkyl ethers; and long chain aliphatic carbonate amides of sucrose β-amino-alkyl ethers.

[0136] Thus, as noted above, the hydrophobic alkyl should be selected from any desired size depending on the desired hydrophobicity and hydrophilicity of the saccharide moiety. For example, one preferred range for the alkyl chain is from about 9 to about 24 carbon atoms. Even more preferred ranges are from about 9 to about 16, or about 14 carbon atoms. Similarly, preferred glycosides include maltose, sucrose, and glucose linked by glycosidic bonds to alkyl chains of 9, 10, 12, 13, 14, 16, 18, 20, 22, or 24 carbon atoms, such as nonyl-, decyl-, dodecyl-, and tetradecyl sucrosides, glucosides, and maltosides. These compositions are nontoxic and amphiphilic because they are broken down into alcohols or fatty acids and oligosaccharides. Furthermore, the bond between the hydrophobic alkyl group and the hydrophilic saccharide may comprise a glycosidic, thioglycosidic, amide, ureido, or ester bond, among other possibilities.

[0137] As used herein, "saccharide" includes monosaccharides, oligosaccharides, or polysaccharides in the form of linear or cyclic chains, or combinations thereof to form saccharide chains. Oligosaccharides are saccharides that have two or more monosaccharide residues. Thus, examples of saccharides include glucose, maltose, maltotriose, maltotetraose, sucrose, and trehalose.

[0138] In one embodiment, the exemplary alkyl saccharide is an alkyl maltoside. An alkyl maltoside is a glycoside of the disaccharide maltose and an alcohol. Typical alkyl maltosides are dodecyl maltoside, tetradecyl maltoside, and hexadecyl maltoside, which consist of 12, 14, and 16 carbon straight chain alcohols glycosidically linked to maltose, respectively. In an exemplary embodiment, the alkyl glycoside is tetradecyl maltoside.

[0139] For example, one of the alkyl saccharides is 1-On-dodecyl-β-D-maltopyranoside (alternatively, lauryl-β-D-maltopyranoside, dodecylmaltopyranoside, dodecylmaltoside, Intravail®, and DDM;C 24 H 46 Q 11 Alkyl saccharides are used in commercial food and personal care products and are designated as "Generally Recognized as Safe" (GRAS) substances for food use. They are odorless, tasteless, nontoxic, nonmutagenic, and non-irritating transmucosal absorption enhancers that are non-sensitizing up to 25% concentration in the Draize test. Alkyl saccharides increase absorption by increasing paracellular permeability as indicated by a decrease in transepithelial electrical resistance. Alkyl saccharides may also increase transcytosis. This effect is short-lived. Other alkyl saccharides include tetradecyl maltoside (TDM) and sucrose dodecanoate.

[0140] In sugar chemistry, an anomer is any of a pair of cyclic stereoisomers of a sugar or glycoside (called α or β) that differ only in the configuration at the hemiacetal (or hemiketal) carbon, also called the anomeric or reducing carbon. If this structure resembles that of glucose with the hydroxyl group on the anomeric carbon at the axial position, the sugar is an α anomer. However, if this hydroxyl is at the equatorial position, the sugar is a β anomer. For example, the two cyclic forms of glucose are anomers: α-D-glucopyranose and β-D-glucopyranose. Similarly, alkyl glycosides also occur as anomers. For example, dodecyl β-D-maltoside and dodecyl α-D-maltoside are the two cyclic forms of dodecyl maltoside. The two different anomers are two separate chemical structures and therefore have different physical and chemical properties. In one aspect of the invention, the alkyl glycoside of the invention is the β anomer. In an exemplary aspect, the alkyl glycoside is the β anomer of an alkyl maltoside, such as tetradecyl-β-D-maltoside (TDM).

[0141] Thus, in one aspect of the present invention, the alkyl glycoside used is a substantially pure alkyl glycoside. As used herein, a "substantially pure" alkyl glycoside refers to one anomeric form of an alkyl glycoside (either the α- or β-anomer form) containing less than about 2% of other anomeric forms, preferably less than about 1.5% of other anomeric forms, more preferably less than about 1% of other anomeric forms. In one aspect, a substantially pure alkyl glycoside contains more than 98% of the α- or β-anomer. In another aspect, a substantially pure alkyl glycoside contains more than 99% of the α- or β-anomer. In another aspect, a substantially pure alkyl glycoside contains more than 99.5% of the α- or β-anomer. In another aspect, a substantially pure alkyl glycoside contains more than 99.9% of the α- or β-anomer.

[0142] In certain embodiments, the intranasal formulation comprises about 0.001% to about 5.0% by weight of dodecyl maltoside. In certain embodiments, the intranasal formulation comprises about 0.01% to about 2.5% of dodecyl maltoside. In certain embodiments, the intranasal formulation comprises about 0.05% to about 2.5% of dodecyl maltoside. In certain embodiments, the intranasal formulation comprises about 0.1% to about 0.5% of dodecyl maltoside. In certain embodiments, the intranasal formulation comprises about 0.15% to about 0.35% of dodecyl maltoside. In certain embodiments, the intranasal formulation comprises about 0.15% to about 0.2% of dodecyl maltoside. In certain embodiments, the intranasal formulation comprises about 0.18% dodecyl maltoside. In certain embodiments, the intranasal formulation comprises about 0.2% to about 0.3% of dodecyl maltoside. In certain embodiments, the intranasal formulation comprises about 0.25% dodecyl maltoside.

[0143] When 0.18% dodecylmaltoside was added to an intranasal formulation of sumatriptan, the maximum plasma concentration increased nearly fourfold compared with the Imitrex nasal spray, and T max was reduced from 1-2 hours to 8-10 minutes. Total exposure increased by 32% as measured by area under the concentration-time curve (AUC). Intranasal formulations of naltrexone have the potential to be used to treat AUD without the use of needles or sustained release formulations. Inclusion of dodecyl maltoside may improve pharmacokinetic parameters for some applications.

[0144] Some absorption-enhancing excipients can alter the paracellular and / or transcellular pathways, while others can extend residence time in the nasal cavity or prevent metabolic changes. Whereas the molecular weight limit for nasal absorption without an absorption enhancer is approximately 1 kDa, administration of a drug with an absorption enhancer allows absorption of molecules between 1 and 30 kDa. However, intranasal administration of most absorption enhancers can cause nasal mucosa damage. Maggio, J. Excipients and Food Chem. 5(2):100-12, 2014.

[0145] Examples of absorption enhancers include aprotinin, benzalkonium chloride, benzyl alcohol, capric acid, ceramide, cetylpyridinium chloride, chitosan, cyclodextrin, deoxycholic acid, decanoylcarnitine, dodecylmaltoside, EDTA, glycocholic acid, glycodeoxycholic acid, glycofurol, glycosylated sphingosine, glycyrrhetinic acid, 2-hydroxypropyl-β-cyclodextrin, laureth-9, lauric acid, lauroyl glycerol, glyceryl sphingosine ... These include: ylcarnitine, lauryl sulfate, lysophosphatidylcholine, menthol, poloxamer 407, poloxamer F68, poly-L-arginine, polyoxyethylene-9-lauryl ether, polysorbate 80, propylene glycol, quillaja saponin, salicylic acid, beta-sitosterol-beta-D-glucoside, sucrose coconut, taurocholic acid, taurodeoxycholic acid, taurodihydrofusidic acid, and tetradecyl maltoside.

[0146] The opioid antagonist naltrexone described herein can be formulated into pharmaceutical compositions using techniques well known to those skilled in the art. Suitable pharma- ceutically acceptable carriers other than those mentioned herein are known in the art.

[0147] The opioid antagonist naltrexone described herein may optionally be present as a pharma- ceutically acceptable salt, including pharma-ceutically acceptable acid addition salts prepared from pharma-ceutically acceptable non-toxic acids, including inorganic and organic acids.Representative acids include, but are not limited to, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethenesulfonic acid, dichloroacetic acid, formic acid, fumaric acid, gluconic acid, glutamic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, oxalic acid, p-toluenesulfonic acid, and the like, for example, pharma-ceutically acceptable salts described in Berge et al., Journal of Pharmaceutical Sciences, 66:1-19 (1977). The acid addition salts may be obtained as a direct product of compound synthesis. Alternatively, the free base may be dissolved in a suitable solvent containing a suitable acid, and the salt may be isolated by evaporating the solvent or by other methods to separate the salt and the solvent. The opioid antagonist naltrexone described herein may form solvates with standard low molecular weight solvents using methods known to those skilled in the art.

[0148] Thus, provided herein is a pharmaceutical formulation for intranasal administration comprising naltrexone or a salt thereof, e.g., naltrexone hydrochloride. In certain embodiments, the formulation is an aqueous solution. In certain embodiments, the formulation comprises about 25 to about 200 μL of aqueous solution per dose. In certain embodiments, the formulation comprises about 50 to about 200 μL of aqueous solution per dose. In certain embodiments, the formulation comprises about 140 μL or less per dose. In certain embodiments, the formulation comprises about 100 μL or less per dose.

[0149] In certain embodiments, the formulation comprises about 1% (w / w) to about 4% (w / w) naltrexone hydrochloride. In certain embodiments, the formulation comprises about 1% (w / w) to about 3% (w / w) naltrexone hydrochloride. In certain embodiments, the formulation comprises about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, about 2.0, about 2.1, about 2.2, about 2.3, about 2.4, about 2.5, about 2.6, about 2.7, about 2.8, about 2.9, about 3.0, about 3.1, about 3.2, about 3.3, about 3.4, about 3.5, about 3.6, about 3.7, about 3.8, about 3.9, or about 4.0% (w / w) naltrexone hydrochloride. In certain embodiments, the formulation comprises about 1.2% (w / w) naltrexone hydrochloride. In certain embodiments, the formulation comprises about 1.6% (w / w) naltrexone hydrochloride. In certain embodiments, the formulation comprises about 2% (w / w) naltrexone hydrochloride. In certain embodiments, the formulation comprises about 3% (w / w) naltrexone hydrochloride.

[0150] In certain embodiments, the formulation contains about 1 mg to about 4 mg of naltrexone hydrochloride. In certain embodiments, the formulation contains about 1 mg to about 3 mg of naltrexone hydrochloride. In certain embodiments, the formulation contains about 2 mg to about 4 mg of naltrexone hydrochloride. In certain embodiments, the formulation contains about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, about 2.0, about 2.1, about 2.2, about 2.3, about 2.4, about 2.5, about 2.6, about 2.7, about 2.8, about 2.9, about 3.0, about 3.1, about 3.2, about 3.3, about 3.4, about 3.5, about 3.6, about 3.7, about 3.8, about 3.9, or about 4.0 mg of naltrexone hydrochloride. In certain embodiments, the formulation contains about 1.2 mg of naltrexone hydrochloride. In certain embodiments, the formulation contains about 1.6 mg of naltrexone hydrochloride. In certain embodiments, the formulation contains about 2 mg of naltrexone hydrochloride. In certain embodiments, the formulation contains about 3 mg of naltrexone hydrochloride.

[0151] Aqueous formulations for intranasal administration disclosed herein may also include pharma- ceutically acceptable excipients, such as one or more isotonicity agents, one or more preservatives, one or more stabilizers, one or more absorption enhancers, and one or more agents to adjust the pH or buffer the solution.

[0152] In certain embodiments, the intranasal formulation further comprises an isotonic agent, such as sodium chloride (NaCl).

[0153] In certain embodiments, the intranasal formulation further comprises a compound that is a preservative and / or a surfactant.

[0154] In certain embodiments, the preservative and / or surfactant is selected from benzalkonium chloride, methylparaben, sodium benzoate, benzoic acid, phenylethyl alcohol, and the like, and mixtures thereof; surfactants, such as polysorbate 80NF, polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene (4) sorbitan monolaurate, polyoxyethylene 20 sorbitan monopalmitate, polyoxyethylene 20 sorbitan monostearate, polyoxyethylene (4) sorbitan monostearate, polyoxyethylene 20 sorbitan tristearate, polyoxyethylene (5) sorbitan monooleate, polyoxyethylene 20 sorbitan trioleate, polyoxyethylene 20 sorbitan monoisostearate, sorbitan monooleate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan trilaurate, sorbitan trioleate, sorbitan tristearate, and the like, and mixtures thereof.

[0155] In certain embodiments, the intranasal formulation further comprises a stabilizer.

[0156] In certain embodiments, the stabilizer is edetate disodium (EDTA).

[0157] In certain embodiments, the pharmaceutical composition is in about 100 μL of aqueous solution.

[0158] In certain embodiments, when the pharmaceutical composition is delivered nasally to the patient, less than about 10% of the pharmaceutical composition leaves the nasal cavity via drainage into the nasopharynx or exterior.

[0159] Nasal drug delivery devices and kits Also provided is a pharmaceutical composition in a device adapted for nasal delivery to a subject suffering from AUD, comprising a therapeutically effective amount of the opioid antagonist naltrexone or a pharma- ceutically acceptable salt thereof.In certain embodiments, the device is pre-primed.In certain embodiments, the device can be primed before use.In certain embodiments, the device can be operated with one hand.

[0160] Nasal delivery is considered an attractive route for systemic drug delivery, especially when rapid absorption and efficacy are desired. Furthermore, nasal delivery may help address issues related to unpleasant taste, poor bioavailability, slow absorption, drug degradation, and adverse events (AEs) within the gastrointestinal tract, and avoids first-pass metabolism and liver toxicity associated with chronic oral naltrexone use.

[0161] Liquid nasal formulations are primarily aqueous solutions, although suspensions and emulsions can also be delivered.

[0162] Several emergency medical services (EMS) programs have developed a system for intranasally administering the opioid antagonist naloxone using existing technology and existing medical devices for approved drugs, albeit in a manner not approved by the FDA. This has been accomplished by using an injectable formulation (1 mg / mL) and administering 1 mL per nostril via a commercially available nasal atomizer / nebulizer device. The system combines an FDA approved naloxone injection product (without a needle and a luer-fit tip) with a commercially available medical device called the Mucosal Atomization Device (MAD™ Nasal, Wolfe Tory Medical, Inc.). This initiative is consistent with the US Needlestick Safety and Prevention Act (Public Law 106-430). EMS programs have acknowledged limitations of this system, one of which is that it is not assembled and ready to use. Although this method of administration appears to be effective in reversing narcosis, the formulation does not collect in a centralized location to be retained in the nasal cavity. The delivery volume of 1 mL per nostril is greater than that typically used for intranasal drug administration. Thus, drug is lost from the nasal cavity by drainage into the nasopharynx or externally from the nasal cavity. The device described herein is an improved ready-to-use product that is optimized, centralized, and formulated specifically for nasal delivery.

[0163] Metered dose spray pumps have dominated the nasal drug delivery market since their introduction, typically delivering 100 μL (or other volumes ranging from 25 to 200 μL and greater) per spray and demonstrating high reproducibility of emitted dose and plume shape in in vitro studies.

[0164] Examples of standard metered dose spray pumps include metered dose spray pumps supplied by Aptar Pharma, Inc., such as the multi-dose "classic technology platform" nasal sprayer device. Such devices include a reservoir that holds multiple doses (e.g., 50, 100, 150, 200, 60, or 120 doses) of the nasal spray formulation, a closure (e.g., screw, crimp, or snap-on), and an actuator that delivers 45-1000 μL (e.g., 50 μL, 100 μL, 140 μL, 150 μL, or 200 μL) of fluid per actuation to contain a single dose. The actuator may be configured to count doses, deliver gel formulations, deliver in an upside-down configuration, and the like.

[0165] In conventional spray pump systems, antimicrobial preservatives are usually required to maintain the microbiological stability of the liquid formulation. However, preservative-free systems are also available, such as Aptar's Advanced Preservative Free (APF) system. Aptar's Advanced Preservative Free (APF) system is vented, has a filter membrane for airflow to prevent contamination, has a metal-free fluid path for oxygenating the formulation, and can be used in any orientation. Additional nasal sprayer devices, such as Aptar, are optimized with dispenser tips that prevent clogging (useful for high viscosity and volatile formulations), actuators that do not require repriming even after extended periods of non-use, and the like.

[0166] The particle size and plume shape may vary within certain limits and depend on the pump characteristics, the formulation, the actuator orifice, and the applied force. The droplet size distribution of nasal sprayers is an important parameter as it has a significant effect on the in vivo deposition of the drug in the nasal cavity. The droplet size is influenced by the device's operating parameters and the formulation. The typical median droplet size should be about 30 to about 100 μm. If the droplets are too large (> about 120 μm), deposition occurs mainly in the anterior part of the nose. If the droplets are too small (< about 10 μm), they may be inhaled and reach the lungs in some cases. This must be avoided for safety reasons. As a surfactant, benzalkonium chloride can affect the surface tension of the droplets from the delivered nasal spray plume, resulting in spherical or substantially spherical particles with a narrow droplet size distribution (DSD), as well as affect the viscosity of the liquid formulation.

[0167] The plume shape, droplet size, and DSD of the plume delivered after spraying can be measured under specified experimental and instrumental conditions by suitable and validated and / or calibrated analytical procedures known in the art. These include photography, laser diffraction, and impaction systems (cascade impaction, NGI). Plume shape, droplet size, and DSD can be measured by C max , T max These may affect pharmacokinetic outcomes such as drug resistance and linear dose proportionality.

[0168] The droplet size distribution can be controlled by the range of D10, D50, D90, span [(D90-D10) / D50], and the percentage of droplets less than 10 mm. In certain embodiments, the formulation has a narrow DSD. In certain embodiments, the formulation has a D(v,50) of 30-70 μm and a D(v,90) of <100 μm.

[0169] In certain embodiments, the percentage of droplets less than 10 μm is less than 10%. In certain embodiments, the percentage of droplets less than 10 μm is less than 5%. In certain embodiments, the percentage of droplets less than 10 μm is less than 2%. In certain embodiments, the percentage of droplets less than 10 μm is less than 1%.

[0170] In certain embodiments, the formulation, when operatively dispensed from the device, produces a uniform, circular plume with an ovality ratio close to 1. The ovality ratio is the maximum diameter (D) of the spray pattern perpendicular to the direction of the spray stream (e.g., from the "top"). max ) and minimum diameter (D min ) In certain embodiments, the ellipse ratio is less than ±2.0. In certain embodiments, the ellipse ratio is less than ±1.5. In certain embodiments, the ellipse ratio is less than ±1.3. In certain embodiments, the ellipse ratio is less than ±1.2. In certain embodiments, the ellipse ratio is less than ±1.1. In certain embodiments, the ellipse ratio is about ±1.0.

[0171] The details of particle generation and mechanical principles of different types of nasal aerosol devices have been described. They are reviewed in Vidgren and Kublik, Adv. Drug Deliv. Rev. 29:157-77, 1998. Conventional spray pumps replace the expelled liquid with air, and therefore require a preservative to prevent contamination. However, prompted by studies suggesting possible adverse effects of preservatives (e.g. irritation of the nasal mucosa), pump manufacturers have developed various spray systems that do not require preservatives. These systems use collapsible bags, movable pistons, or compressed gas to make up the expelled liquid volume (www.aptar.com and www.rexam.com). The collapsible bag and movable piston solution to make up the expelled liquid volume has the added advantage that it can be expelled upside down without the risk of air being sucked into the dip tube and compromising the subsequent spray. This may be useful for some products where the patient is bedridden and head-down application is recommended. Another method used to avoid preservatives is where the air replacing the released liquid is filtered through a sterile air filter. Additionally, some systems have a ball valve at the tip to prevent contamination of the liquid in the applicator tip (www.aptar.com). More recently, a side-actuation pump has been designed and introduced to deliver fluticasone furoate for the indications of seasonal and perennial allergic rhinitis. This pump was designed with an even shorter tip to avoid contact with sensitive mucosal surfaces. New designs to reduce the need for priming and repriming as well as pumps incorporating pressure point features to improve dose reproducibility and dose counters as well as lockout mechanisms to enhance dose management and safety are available (www.rexam.com and www.aptar.com).

[0172] Conventional simple metered dose spray pumps require priming and some degree of overfill to maintain dose consistency with the labeled number of doses. Conventional simple metered dose spray pumps are well suited for drugs administered daily over a long period of time, but due to priming procedures and poor control of dosing, they are less suited for drugs with narrow therapeutic time windows, especially when used infrequently, unless a specialized device is selected. For expensive drugs and vaccines intended for single administration or single use, and where strict control of dose and formulation is particularly important, single-dose or bi-dose spray devices are preferred (www.aptar.com). A simple variation of the single-dose spray device (MAD™) is offered by LMA (LMA, Salt Lake City, UT, USA; www.lmana.com). A nosepiece with a spray tip is fitted onto a standard syringe. First, the liquid drug to be delivered is drawn into the syringe, and then the spray tip is fitted onto the syringe. This device has been used in academic research to deliver topical steroids in chronic sinusitis patients, for example, and in vaccine research. A single- or double-dose prefilled device based on the same principle (Accuspray™, Becton Dickinson Technologies, Research Triangle Park, NC, USA; www.bdpharma.com) is used to deliver the influenza vaccine FluMist™ (www.flumist.com) and is approved for the US market for both adults and children. A similar two-dose device was marketed by a Swiss company ten years ago to deliver another influenza vaccine.

[0173] Pre-primed single-dose and bi-dose devices are also available and consist of a reservoir, piston, and swirl chamber (see, for example, Aptar's, formerly Pfeiffer's, UDS UnitDose™ and BDS BiDose™ devices). A spray is formed as the liquid is forced through the swirl chamber. These devices are held between the middle and ring fingers, with the thumb on the actuator. A pressure point mechanism incorporated into some devices ensures repeatability of actuation force and emitted plume characteristics. Currently, over-the-counter nasal migraine medications such as Imitrex® (www.gsk.com) and Zomig® (www.az.com; Pfeiffer / Aptar single-dose device), the over-the-counter influenza vaccine Flu-Mist (www.flumist.com; Becton Dickinson single-dose spray device), and the intranasal naloxone formulation for opioid overdose rescue, Narcan Nasal® (narcan.com; Adapt Pharma), are delivered using this type of device.

[0174] In certain embodiments, the 90% confidence interval for the dose delivered per actuation is about ±2%. In certain embodiments, the 95% confidence interval for the dose delivered per actuation is about ±2.5%.

[0175] Historically, intranasal administration of drugs in large volumes, for example, intranasal administration from a syringe fitted with a mucosal atomizer device, has encountered difficulties due to the tendency of some of the formulation to drip out of the nostril or down the nasopharynx.Thus, in certain embodiments, when the pharmaceutical composition is delivered to the patient, less than about 20% of the pharmaceutical composition leaves the nasal cavity and drains into the nasopharynx or outside via drainage.In certain embodiments, when the pharmaceutical composition is delivered to the patient, less than about 10% of the pharmaceutical composition leaves the nasal cavity and drains into the nasopharynx or outside via drainage.In certain embodiments, when the pharmaceutical composition is delivered to the patient, less than about 5% of the pharmaceutical composition leaves the nasal cavity and drains into the nasopharynx or outside via drainage.

[0176] Current container closure system designs for inhalation spray drug products include both pre-metered and device metered presentations that use mechanical or power assistance and / or energy from patient inspiration for spray plume generation. Pre-metered presentations comprise a pre-measured dose or dose fraction in some type of unit (e.g., one or more blisters or other cavities) that is then inserted into the device during manufacture or by the patient prior to use. A typical device metering unit has a reservoir containing enough formulation for multiple doses that are delivered as a metered spray by the device itself upon patient activation.

[0177] A new nasal drug delivery method is the breath-powered Bi-Directional™ technology, which can be adapted to any type of dispersion technology, both liquid and powder. This concept utilizes the natural functional aspects of the upper airway to provide a delivery method that can overcome many of the inherent limitations of conventional nasal devices. The breath-powered Bi-Directional™ device consists of a mouthpiece and a sealing nosepiece with an optimized frustoconical shape and a soothing surface that mechanically widens the first part of the nasal valve. The user slides the sealing nosepiece into one nostril until it seals with the pliable soft tissue of the nostril opening, where it mechanically widens the narrow, slit-shaped part of the triangular nasal valve. The user then exhales through the attached mouthpiece. As the user exhales into the mouthpiece against the resistance of the device, the soft palate (or velum) automatically rises due to the positive pressure of the oropharynx, isolating the nasal cavity from the rest of the respiratory system. This mechanism allows for the release of liquid or powder particles into a stream of air that enters one nostril, passes completely through the nasal septum, and exits through the opposite nostril.

[0178] Aseptic filling does not require the use of preservatives in the device, but overfilling is required, resulting in a waste fraction similar to that of metered dose multi-dose sprays. To deliver 100 μL, the device used for the intranasal migraine medications Imitrex™ (sumatriptan) and Zomig™ (zolmitriptan) (Pfeiffer / Aptar single-dose device) is filled with a volume of 125 μL, and about half that for the bi-dose design. Sterile drug products may be produced using aseptic processing or terminal sterilization methods. Terminal sterilization methods typically involve filling and sealing product containers under high quality environmental conditions. The product is filled and sealed in this type of environment to minimize the microbial and particulate content of the in-process product, as well as to aid in the success of the subsequent sterilization process. In most cases, the product, container, and closure have a low level of biological contamination, but are not sterile. The product in the final container is then subjected to a sterilization process, such as heat or radiation. In aseptic processing, the drug product, containers, and closures are first subjected to a sterilization method separately, as appropriate, and then combined. Since there is no process to sterilize the product inside the final container, it is important that the container is filled and sealed in an extremely high quality environment. Aseptic processing involves more variables than terminal sterilization. Before being aseptically assembled into the final product, the individual parts of the final product are typically subjected to various sterilization processes. For example, glass containers are subjected to dry heat, rubber closures are subjected to moist heat, and liquid dosage forms are subjected to filtration. Each of these manufacturing processes requires validation and control.

[0179] Treatment Provided herein are methods for treating alcohol use disorder and related conditions, comprising intranasal administration of a therapeutically effective amount of naltrexone, or a salt or hydrate thereof.

[0180] Sinclair method and variations The Sinclair Method is an AUD treatment that utilizes pharmacological extinction - the use of opioid antagonists such as naltrexone - to change the habit-forming behavior of drinking into a habit-erasing behavior. This effect returns a person's alcohol craving to a pre-addiction state.

[0181] The method comprises a subject taking an oral dose of naltrexone about 1 hour, about 2 hours, about 3 hours, or about 4 hours before consuming alcohol. This pre-ingestion dose of oral naltrexone disrupts the body's behavior and reward cycle, thereby making the subject want to drink less, rather than more. Most importantly, studies have shown that this methodology is equally effective with or without therapy, so subjects can choose whether to combine this treatment method with other therapies without adversely affecting actual physical results. Importantly, unlike other currently approved pharmacotherapeutic treatments for AUD, the Sinclair Method requires the use of oral naltrexone while the individual continues their normal drinking behavior. As a result, retention with this pharmacotherapeutic treatment protocol is expected to be significantly higher than abstinence alone.

[0182] Using the Sinclair technique, AUDs can be eradicated within 6 months. However, the efficacy of oral naltrexone is hampered by its slow onset and very low bioavailability. High levels of the peripherally selective active metabolite 6-β-naltrexol and injectable naltrexone by itself present obvious difficulties related to needles, including the need for practitioner administration at regularly scheduled intervals. Thus, intranasal administration of naltrexone in a pre-primed single-use or multi-use nasal spray pump and the use of absorption enhancers should significantly improve the outcome of AUD treatment. The timing of administration may also affect efficacy. Intranasal formulations of naltrexone are rapidly absorbed, thus providing a rapid onset of action without the need for needles and high bioavailability.

[0183] Accordingly, disclosed herein is a method of treating an alcohol use disorder or related condition in a subject, the method comprising administering to the subject an intranasal formulation comprising a therapeutically effective amount of naltrexone or a pharma- ceutically acceptable salt thereof.

[0184] In certain embodiments, an intranasal formulation containing naltrexone is administered prior to alcohol consumption.

[0185] In certain embodiments, the intranasal formulation containing naltrexone is administered about 1 to about 2 hours before alcohol ingestion. In certain embodiments, the intranasal formulation containing naltrexone is administered about 1 hour before alcohol ingestion. In certain embodiments, the intranasal formulation containing naltrexone is administered about 0.5 to about 1 hour before alcohol ingestion. In certain embodiments, the intranasal formulation containing naltrexone is administered about 10 to about 30 minutes before alcohol ingestion. In certain embodiments, the intranasal formulation containing naltrexone is administered about 5 to about 10 minutes before alcohol ingestion. In certain embodiments, the intranasal formulation containing naltrexone is administered immediately before alcohol ingestion.

[0186] In certain embodiments, an intranasal formulation containing naltrexone is administered simultaneously with alcohol consumption.

[0187] In certain embodiments, the intranasal formulation containing naltrexone is administered shortly after alcohol ingestion, hi certain embodiments, the intranasal formulation containing naltrexone is administered within one hour after alcohol ingestion begins.

[0188] Because intranasal naltrexone is rapidly taken up through the nasal mucosa and appears quickly in plasma, as evidenced by the studies below, it is expected that intranasal administration will enable a subject to take naltrexone immediately prior to, or even concomitantly with, or after alcohol ingestion and experience a benefit, e.g., elimination, reduction, etc. of cravings, etc. Absorption enhancers are expected to facilitate this effect.

[0189] In certain embodiments, the alcohol use disorder is alcohol abuse. In certain embodiments, the alcohol use disorder is alcohol dependence. In certain embodiments, the alcohol use disorder is alcohol addiction.

[0190] It is anticipated that these approaches will also be effective in treating other substance use disorders and reward-based disorders.

[0191] The methods disclosed herein can be accomplished by administering various embodiments of the formulations disclosed herein, for example, in the section "Pharmaceutical Formulations" above, the embodiments above, and in the Examples below. The formulations can be administered using devices known in the art, for example, the devices disclosed herein in the section entitled "Nasal Drug Delivery Devices and Kits."

[0192] Also provided herein are embodiments in which any of the above embodiments may be combined with any one or more other embodiments, provided that such combinations are not mutually exclusive. EXAMPLES

[0193] The following examples are included to demonstrate preferred embodiments of the present invention. The following examples are presented for illustrative purposes only and are presented to assist those skilled in the art in using the present invention. The examples are not intended to limit the scope of the present invention in any manner. Those skilled in the art, upon consideration of this disclosure, should understand that many changes can be made to the specific embodiments disclosed and still obtain the same or similar results without departing from the spirit and scope of the present invention.

[0194] Example 1: Intranasal Naltrexone Protocol for Treating Alcohol Use Disorder Individuals with alcohol use disorder (AUD) are treated with intranasal naltrexone and examined for abstinence, reduced alcohol consumption, and / or elimination of alcohol consumption. It is believed that individuals with AUD release endogenous opioids when they consume alcohol. The binding of these opioids to receptors in the brain may be responsible for the positive reinforcing effects of alcohol. Drinking alcohol while the opioid antagonist naltrexone blocks the positive reinforcement from alcohol should eliminate drinking and alcohol craving.

[0195] In one example protocol, subjects with AUD (e.g., about 10-20) are admitted to a study facility as inpatients. An initial visit serves the purpose of screening, confirming diagnosis, and obtaining informed consent. During their inpatient stay (e.g., one or several weeks), each subject is given a placebo or an intranasal dose of naltrexone followed by consumption of one or more alcoholic beverages. Naltrexone is administered at a specified dose and by a specified method about 0.25 hours to about 4 hours prior to alcohol consumption. One example of a dosing treatment is an intranasal formulation delivering about 1 to about 4 mg of naltrexone hydrochloride per dose delivered by a single or multiple use spray device. Another example of a dosing treatment is an intranasal formulation delivering a first dose of 3 mg naltrexone hydrochloride in the morning followed by later doses of 3 mg naltrexone hydrochloride throughout the day as needed by the patient. Yet another example of a medication treatment is an intranasal formulation that delivers up to 12 mg of naltrexone hydrochloride per day. Intranasal formulations of naltrexone may or may not contain an absorption enhancer, such as Intravail®.

[0196] Intranasal naltrexone is expected to improve post-treatment inhibition of alcohol intake. Intranasal naltrexone is also expected to reduce alcohol craving and shorten the time required for a subject to demonstrate pharmacological extinction of alcohol craving.

[0197] Approximately 1 hour prior to dosing, an ECG, blood pressure, heart rate, and respiration rate are taken and the time recorded. An ECG is repeated approximately 1 and 4 hours after dosing and the time recorded. Vital signs including sitting (after 5 minutes) heart rate, blood pressure, and respiration rate are taken prior to dosing and approximately 1 and 4 hours after each dose. Adverse events (AEs) are recorded and treatment terminated if necessary. The nasal passages are examined pre-dose, after intranasal administration only, and at 5, 30, 60 minutes, 4, and 24 hours after dosing.

[0198] ECGs and vital signs will be checked once daily at screening, admission, and discharge. Vital signs will also be checked once the day after naltrexone administration. AEs will be assessed by subject spontaneous reporting, by examining the nasal mucosa, and by measuring vital signs, ECG, and clinical examination parameters.

[0199] Example 2: Pharmacokinetic Data Analysis Noncompartmental pharmacokinetic (PK) parameters (C max , T max , AUC o-t , AUC o-∞ , t 1 / 2 , λ z , and apparent clearance (CL / F, naltrexone only). PK parameters of various AUD treatment protocols (e.g., 4 mg intranasal; 50 mg oral tablet with or without absorption enhancers such as alkyl saccharides) will be compared to a 2 mg intramuscular (IM) dose of naltrexone. AUC and C max Dose-adjusted values ​​of AUC are calculated. The relative extent of intranasal (IN) and oral (PO) absorption is estimated from the dose-adjusted AUC. Within an ANOVA framework, IN-transformed PK parameters are compared for IN and PO vs. IM naltrexone treatments. AUC and C are used to compare each treatment with IM naltrexone. maxConstruct 90% confidence intervals for the ratios of the geometric least squares means of the parameters (IN / IM and PO / IM). These 90% confidence intervals are obtained by exponentiating the 90% confidence intervals of the differences between the least squares means based on a log scale.

[0200] AEs are coded using the latest version of the Medical Dictionary for Regulatory Affairs (MedDRA) Preferred Terms and classified by System Organ Class (SOC) name. Severity, frequency, and relationship of the AE to study drug are indicated by preferred terms according to SOC classification. Separate summaries are provided during the four study periods, i.e., after each dose of study drug and until the time of the next dose of study drug or clinic discharge. A list of each individual AE is provided, including start date, stop date, severity, relationship, outcome, and duration.

[0201] Clinically meaningful changes in vital signs, ECG, and clinical examination parameters were expressed as numbers and percentages by dosing session.

[0202] Example 3: Dose Selection and Pharmaceutical Compositions Containing Absorption Enhancers Intranasal naltrexone may optionally be formulated with absorption enhancing excipients.

[0203] One such excipient is the alkyl saccharide Intravail®. The concentration of Intravail® in nasal formulations is typically 0.1% to 0.2% by weight. A concentration of 0.25% by weight of alkyl saccharide is used in this study. A concentration of 25% of Intravail® was non-irritating in the rabbit eye model. The oral "no observable effect level" was approximately 20,000-30,000 mg / kg body weight. Although there are no comparable intranasal data, the basic lack of oral safety suggests that the amount of alkyl saccharide required for nasal toxicity is considerably higher than that administered in this study.

[0204] In this study, a single dose of naltrexone was administered in four different ways: (a) 4 mg IN dissolved in sterile water for injection; (b) 4 mg IN dissolved in sterile water for injection with 0.25% Intravail®; (c) 2 mg as an IM injection; and (d) a 50 mg oral tablet. Intranasal administration is expected to increase the rate of absorption compared to oral administration. The addition of Intravail® is expected to further increase the rate of absorption from the nasal cavity.

[0205] Example 4: Pharmacokinetic evaluation of intranasal naltrexone Purpose of the test The objectives of this clinical study consisted of two parts: to determine the pharmacokinetics of two intranasal formulations of naltrexone (4 mg with Intravail® and 4 mg without Intravail®) and one oral formulation (50 mg tablet) compared to a 2 mg intramuscular dose of naltrexone, and to determine the safety of intranasal naltrexone, particularly with respect to nasal irritation symptoms, e.g., inflammation (erythema, edema, and erosion) and bleeding. Towards this goal, the primary endpoint of the study was the pharmacokinetic parameters (C ) of the IN and oral naltrexone formulations compared to a 2 mg IM dose of naltrexone. max , T max , AUC 0-t , and AUC 0-inf Secondary endpoints included adverse events (AEs), changes in vital signs (heart rate, sitting blood pressure, and respiratory rate), electrocardiograms (ECGs), clinical findings, and nasal irritation symptoms using the Nasal Irritation Symptoms Scale.

[0206] Study design Fourteen healthy volunteers enrolled and completed all study drug administrations and blood draws for PK assessments. This was an inpatient, open-label, crossover study involving approximately 14 healthy volunteers. Each subject received the respective naltrexone treatment: 4 mg IN (one 0.1 mL spray of a 40 mg / mL solution in one nostril), 4 mg + Intravail® IN (one 0.1 mL spray of a 40 mg / mL solution containing 0.25% Intravail® in one nostril), 2 mg IM, and 50 mg oral tablet. Subjects stayed in the inpatient facility for 13 days to complete the entire study. Subjects were called 3-5 days after discharge to question about AEs since discharge and concomitant medications. Informed consent was obtained from all subjects and all were screened for eligibility to participate in the study, including medical history, physical examination, clinical chemistry, coagulation markers, hematology, infectious disease serology, urinalysis, urine drug and alcohol toxicology screen, vital signs, and ECG.

[0207] The subjects were administered the study medication the day after admission to the clinic, with a 3-day washout period between doses until all treatments were administered. Blood was collected for analysis before dosing and approximately 2.5, 5, 10, 15, 20, 30, 45, 60 minutes, and 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, and 48 hours after administration of the study medication. On the day the study medication was administered, 12-lead ECGs were performed approximately 1 hour before dosing and approximately 1 and 4 hours after dosing. Vital signs were measured before dosing and approximately 1 and 4 hours after dosing.

[0208] The sequence of assessments on dosing days was ECG, vital signs, then PK blood draws when scheduled at the same nominal time. The target time for PK blood draws was considered most critical, and blood draws were considered to have deviated from the protocol if they occurred ±1 min after the scheduled time for the first 60 min of blood draws, or ±5 min after any subsequent scheduled time. ECG and vital signs were collected within a 10-min period before the nominal time of blood draw. ECG and vital signs were checked once daily at screening, admission, and discharge. Vital signs were also checked once the day after naltrexone administration. Clinical examination measurements were repeated after the final PK blood draw before clinic discharge. AEs were assessed by subject spontaneous reporting, by examination of the nasal mucosa, and by measuring vital signs, ECG, and clinical examination parameters.

[0209] Inclusion and Exclusion Criteria: 1. The study enrolled men and women aged 18-55 years (inclusive). Written informed consent was required. Subjects were: 18~30kg / m 2 Body Mass Index (BMI) (inclusive); adequate venous access; Absence of clinically significant concomitant medical conditions as determined by medical history, physical examination, clinical examination, vital signs, and 12-lead ECG; Agree to use an acceptable method of contraception other than oral contraceptives throughout the study and for 90 days (30 days for women) after the last dose of study drug; and Agree to not consume alcohol, beverages containing >500 mg / day of xanthine (e.g., Coca-Cola, tea, coffee, etc.), or grapefruit / grapefruit juice, or participate in strenuous exercise from 72 hours prior to admission until the final blood draw of the study. There had to be.

[0210] The exclusion criteria were: any IN condition, including abnormal nasal anatomy, nasal symptoms (i.e., nasal congestion and / or runny nose, nasal polyps, etc.); had any product sprayed into the nasal passages prior to screening and drug administration; -Has received an investigational drug within 30 days prior to Day 1; have taken prescription or over-the-counter drugs, dietary supplements, herbal products, vitamins, or have recently used opioid pain medications for pain relief (within 14 days of last using any of these products); positive drug urine screen for alcohol, opioids, cocaine, amphetamines, methamphetamines, benzodiazepines, tetrahydrocannabinol (THC), barbiturates, or methadone at screening or admission; Based on medical history, have previous or current opioid dependence, alcohol dependence, or other drug dependence (excluding nicotine and caffeine); consumed, on average, more than 20 cigarettes per day during the month prior to screening or would be unable to abstain from smoking (or refrain from using any nicotine-containing substance) at least 1 hour before and 2 hours after taking a naltrexone dose; systolic blood pressure less than 90mmHg or more than 140mmHg; diastolic blood pressure less than 55 mmHg or greater than 90 mmHg; Respiratory rate less than 8 breaths / min or more than 20 breaths / min; QTcF interval >440 msec in men and >450 msec in women during a standard 12-lead ECG; significant acute or chronic medical illness (in the investigator's judgment); Concomitant medication treatment is likely to be required during the study; -Has donated blood or received a blood transfusion or plasma or platelet apheresis within 60 days prior to Day 1; women who are pregnant, breastfeeding, or planning to become pregnant during the study period or within 30 days after the last dose of naltrexone; positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), or human immunodeficiency virus antibody (HIVAb) at screening; current or recent (within 7 days prior to screening) upper respiratory tract infection; and Abnormal liver function tests (ALT, AST, total bilirubin) >1.5 times the upper limit of normal Includes:

[0211] Study Drugs and Medication Naltrexone hydrochloride (HCI) was obtained from Mallinckrodt Pharmaceuticals. The IN (40 mg / mL) formulation was prepared by Vince & Associates staff pharmacists. The vehicle for the IN formulation was sterile water for injection. The IM formulation (2 mg / mL) was prepared by Vince & Associates staff pharmacists. The vehicle was sterile saline for injection. IN naltrexone was administered using an Aptar multi-dose device with subjects in a reclining position (approximately 45 degrees). Subjects were instructed not to breathe through their nose when receiving the IN dose of naltrexone. IM naltrexone HCI was administered in a single 1 mL injection into the gluteus maximus muscle using a 23 g needle. Oral naltrexone HCI (50 mg tablets) was obtained from a commercial supplier and administered with 240 mL water.

[0212] Naltrexone was administered in the following sequence: 4 mg naltrexone IN, 4 mg naltrexone + Intravail® IN, 2 mg IM, and 50 mg orally on days 1, 4, 7, and 10. Subjects stayed in the inpatient facility for 13 days to complete the entire study and were discharged 2 days after the fourth dose.

[0213] Penalty rating For PK analysis, blood (4 mL) was collected into sodium heparin-containing tubes at pre-dose and at 2.5, 5, 10, 1.5, 20, 30, 45, and 60 min, as well as 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, and 48 h after initiation of study drug administration. Plasma was separated from whole blood and stored frozen at or below 20°C until assayed. Plasma concentrations of naltrexone and 6β-naltrexol were determined by liquid chromatography and tandem mass spectrometry at XenoBiotic laboratories, Inc., Plainsboro, New Jersey.

[0214] Safety assessment Heart rate, blood pressure, and respiratory rate were recorded approximately 1 hour before and 1 and 4 hours after each naltrexone dose. 12-lead ECGs were obtained approximately 1 hour before and 1 and 4 hours after each naltrexone dose. ECGs and vital signs were obtained within 10 minutes before the nominal time for postdose blood sampling. AEs were recorded from the start of study drug administration until clinic discharge. AEs were recorded relative to each dosing session to attempt to identify associations between AEs and the type of naltrexone dose administered. Nasal examinations were performed on day -1 for eligibility purposes, after IN dosing only, and predose, 5 minutes, 30 minutes, 60 minutes, 4 hours, and 24 hours after IN naltrexone administration to assess for evidence of irritation of the nasal mucosa.

[0215] analysis T max , AUC 0-t , and AUC 0-inf , t 1 / 2 , λ z Noncompartmental PK parameters of naltrexone and 6β-naltrexol were determined, including the apparent clearance (CL / F, naltrexone only). Pharmacokinetic parameters of IN and PO naltrexone (C max , T max AUC and C were compared with the pharmacokinetic parameters of IM naltrexone.max Dose adjustment values ​​for were calculated. The relative extent of IN and PO absorption (IN and PO vs. IM) was estimated from the dose-adjusted AUC. Within the ANOVA framework, ln-transformed PK parameters (C max and AUC) were compared. AUC and C were compared to compare each treatment with IM naltrexone. max We constructed 90% confidence intervals for the ratios of the geometric least squares means of the parameters (IN / IM and PO / IM). These 90% CIs were obtained by exponentiating the 90% CIs of the differences between the least squares means based on the ln scale.

[0216] result The results are shown in Tables 1 to 5 below.

[0217] Table 1. Mean (SD) concentrations of naltrexone following single IN, IM, or oral administration to healthy subjects. TIFF2024164155000008.tif169164

[0218] Table 2. Mean CV% PK parameters of naltrexone after administration to healthy subjects TIFF2024164155000009.tif125162NA = Not Applicable;Frel = Bioavailability compared to IM dose. Calculated as the ratio of AUCinf / dose for IN or PO route compared to IM route. a: N=13; b: N=12; c: N=10; d: Median (minimum, maximum)

[0219] After 4 mg of naltrexone was administered IN, the mean concentration at 2.5 minutes was 0.117 ng / mL. When 0.25% Intravail® was added to the formulation, the mean concentration increased 10-fold (1.15 ng / mL) at 2.5 minutes. At 5 minutes, the mean concentrations of naltrexone with and without Intravail® were 11.9 ng / mL and 1.51 ng / mL, respectively, an 8-fold difference. Addition of 0.25% Intravail® to the IN formulation increased Tmax The median time for C decreased from 30 to 10 minutes. max was almost three-fold increased (15.7 vs. 5.35 ng / mL). AUC 0-inf Total exposure was increased by 54% as measured by RT, indicating that the main effect of Intravail® was to increase the absorption rate by more than this magnitude.

[0220] The mean plasma concentrations of naltrexone at 2.5 and 5 minutes after administration of 2 mg IM were 0.678 ng / mL and 1.04 ng / mL, respectively. The mean C max The value of 4.10 ng / mL was 23% less than after a 4 mg IN dose and 74% less than when Intravail® was part of the IN formulation.

[0221] Mean C after oral dosing max The value was 9.34 ng / mL, which was less than that observed after IN dosing with Intravail®, where 50 mg was administered orally, compared to only 4 mg IN.

[0222] The mean terminal half-life (t 1 / 2 ) ranged from 1.97 hours to 2.52 hours after IM and IN administration. 1 / 2 was 6.41 hours.

[0223] AUC 0-inf When values ​​were dose corrected, the relative bioavailability of naltrexone following IN dosing with and without 0.25% Intravail® was 78% and 48%, respectively, compared to IM administration. The relative bioavailability of the oral dose was only 9%, indicating extensive first-pass metabolism by the gastrointestinal tract and liver.

[0224] Statistical analysis of dose-adjusted PK parameters demonstrated that the exposure of the IN dose was estimated based on the geometric least squares mean (GM) dose-adjusted AUC and C max The results suggest that the IM doses of naltrexone and 0.25% Intravail® administered IN reduced C max The oral route provided a dose-adjusted exposure that was greater than that of the IM route in terms of dose (188% between-treatment geometric least squares mean ratio [GMR]) and less than that of the IM route in terms of AUC (76% GMR). For the oral route, the GMR for dose-adjusted naltrexone exposure was approximately 9% of the IM dose.

[0225] Table 3. Mixed-effects ANOVA results for naltrexone pharmacokinetic parameters following intranasal or oral versus intramuscular administration to healthy subjects. TIFF2024164155000010.tif143164GMR=Geometric least squares mean ratio between treatments (expressed as a percentage relative to the reference)

[0226] Mean C of 6β-naltrexol max Values ​​were 1.5 ng / mL after IM administration and approximately 3 ng / mL after IN administration. Cmax was 90.7 ng / mL after a 50 mg oral dose (Tables 2-3). When adjusted for the administered dose, Cmax values ​​were similar for IN and IM dosing (0.833 and 0.838 ng / mL / mg), but were approximately doubled (2.00 ng / mL / mg) after oral dosing.

[0227] AUC 0-inf The AUC values ​​were also significantly increased after oral dosing compared with IN and IM dosing (675 h·ng / mL and 44.0–27.1 h·ng / mL, respectively). The greater extent of naltrexone first-pass metabolism was reflected by the AUC values ​​of 6β-naltrexol compared with naltrexone. 0-inf This was evident in the ratios: after IN and IM dosing the ratios were approximately 2.2-3.7, compared to 25 after oral dosing.

[0228] Metabolite t 1 / 2The mean duration of the response ranged from 12.4 to 13.9 hours and was independent of the route of administration.

[0229] Table 4. Mean (SD) concentrations of 6β-naltrexol following a single IN, IM, or oral dose to healthy subjects. TIFF2024164155000011.tif171165

[0230] Table 5. Mean (CV%) PK parameters of 6β-naltrexol after administration to healthy subjects TIFF2024164155000012.tif97162 * For Tmax, median (min, max) statistics are presented. All other values ​​are presented as mean (percent coefficient of variation). a: N = 13; b: N = 12; c: N = 10; d: median (min, max).

[0231] The mean C of naltrexone after a 4 mg IN dose was approximately doubled in women compared with men. max With the exception of , there were no clinically meaningful differences between genders in naltrexone or 6β-naltrexol PK parameters following IN, IM, or PO administration.

[0232] safety Overall, 10 of 14 subjects (71%) in the safety population experienced at least one AE (in any dosing period and in any association with drug). The most frequent AEs were Nervous System Disorders SOC AEs (7 subjects, 50%), with dizziness being the most frequent AE of any severity or attribution (5 subjects, 36%). No severe AEs and only one moderate AE, a case of dizziness after the first dose (4 mg IN) that was considered related to study drug, were observed. Three subjects experienced unexpected AEs (UAEs, defined as AEs that were not mentioned in the current product package insert with respect to nature, severity, or frequency). Two UAEs were considered unrelated to study drug, and one treatment-related UAE was mild syncope after administration of the first dose (4 mg IN). Three subjects discontinued the study due to AEs (hypertension, syncope, and out-of-range predose vital signs).

[0233] Example 5: Intranasal Naltrexone Formulations The following table provides examples of naltrexone formulations for intranasal administration to treat disorders: Table 6 provides simple aqueous formulations delivered in approximately 100 μL increments, such as the aqueous formulations used in the experiments described above.

[0234] (Table 6) TIFF2024164155000013.tif87131

[0235] Table 7 shows formulations for intranasal administration in 100 μL of aqueous solution containing excipients, such as compounds that act as isotonicity agents, stabilizers, and / or preservatives or surfactants. EDTA is an abbreviation for edetate disodium, and BZK is an abbreviation for benzalkonium chloride.

[0236] (Table 7) TIFF2024164155000014.tif73158TIFF2024164155000015.tif208158

[0237] Examples 1A-45A are also provided which further contain a sufficient amount of hydrochloric acid to give a pH of 3.5 to 5.5. The acid must be a pharma- ceutically acceptable acid, e.g., hydrochloric acid.

[0238] Example 6: Intranasal Naltrexone Formulation Experiments A series of experiments were conducted to identify a naltrexone formulation that would result in a pharma- ceutical suitable intranasal product, as disclosed herein. The formulation had the following characteristics: Contains an effective amount of naltrexone; Naltrexone is rapidly absorbed after administration, resulting in good C max and a relatively short T max is obtained; Forms a solution at room temperature and remains in solution under cold storage conditions or returns to solution when removed from cold storage; Not contaminated with microorganisms; is storage stable, does not form or acquire undesirable impurities, and / or does not discolor over time; and Non-irritating to nasal tissue The present invention has been designed to include at least some, and in certain embodiments, all, of the above.

[0239] Various formulations were tested with the following observations: The 50 mg / mL naltrexone HCl preparation was cloudy at room temperature, indicating incomplete dissolution. The solubility limit of naltrexone HCl dissolved at ambient temperature was determined to be approximately 40 mg / mL. Several preparations were subsequently made at 30 mg / mL. Additionally, these preparations further contained a fixed amount of NaCl (dodecyl maltoside 0.25%) and NaCl (approximately 0.74%), as well as various amounts of preservatives (benzalkonium chloride, 0-0.02%) and stabilizers (EDTA, 0-0.3%). Crystallization behavior and discoloration were monitored visually. All of these formulations formed crystals when stored under refrigerated conditions. Naltrexone solutions tend to turn yellow over time over 0-3 months. Formulations containing 0.2% or 0.3% EDTA did not form yellow solutions, whereas formulations containing 0% or 0.1% EDTA began to turn yellow. The 0.3% EDTA formulation appeared to be least likely to turn yellow over the longest period of time. Various co-solvents were then evaluated for their potential to reduce crystallization of the drug from solution. Polyethylene glycol (PEG), propylene glycol, and benzyl alcohol were tested. PEG-containing formulations did not prevent crystallization. Propylene glycol-containing formulations prevented crystallization but resulted in high osmolality. High osmolality was expected to cause nasal tissue irritation. Benzyl alcohol-containing formulations prevented crystallization at low concentrations. Total solids were observed to be associated with crystallization, and reducing the amount of naltrexone hydrochloride to produce a low concentration and small amount of NaCl to adjust osmolality helped keep the formulation in solution during storage under refrigerated conditions. Four naltrexone formulations suitable for intranasal administration are presented in Example 7 below.

[0240] Example 7: Further formulations of intranasal naltrexone Below are additional naltrexone batch formulation examples, each giving 2000 liquid grams of intranasal formulation for treating disorders including alcohol use disorder, which may be supplied, for example, in approximately 100 μL increments.

[0241] The following examples were prepared as follows: To a tared 4 L batch container with stir bar, 1800.0 grams of water for injection (WFI) was added and mixing was started. 24.0 g, 32.0 g, 40.0 g, or 60.0 g of naltrexone hydrochloride (NH) was added, rinsed 4 times with 5 mL WFI to rinse the NH container, and mixed until the NH was visibly dissolved. While mixing, 5.0 g DDM was added and mixed until visibly dissolved. The same procedure was then performed with 6.0 g EDTA. Next, an initial amount of 12.6 g, 11.7 g, 10.5 g, or 7.9 g of NaCl was added depending on the formulation concentration. NaCl was added intermittently and mixed during addition until visibly dissolved. Next, 40.0 g of BZK 1% stock solution was added while mixing, the BZK 1% stock solution container was rinsed with 10 mL of rinse solution, and mixed until the BZK was visually dissolved. Finally, the pH of the solution was measured using a calibrated pH meter, and if it was above 5.5, it was adjusted accordingly with 10% HCl until it was 3.5-5.5. The target pH was 5.0. This was done by adding dropwise and mixing for 3-5 minutes during the addition. Water was then added QS to approximately 2000.0 g and stirred for 5 minutes.

[0242] TIFF2024164155000016.tif228142

[0243] The above formulations may be tested according to the procedures of Examples A-E above and according to methods known in the art. Some of these formulations are tested in Example 8 below. The pharmacokinetic properties of these formulations are expected to be consistent with those of effective pharmacotherapies intended for the treatment of opioid overdose and for "as needed" use to treat multiple substance use disorders exemplified by alcohol use disorder and other reward-based disorders. These properties include a rapid onset (T) relative to oral administration achievable with these formulations. max These include short elimination time, high plasma concentration, and short half-life.

[0244] Example 8: Pharmacokinetic evaluation of intranasal naltrexone A single-center, open-label, randomized, four-sequence, four-treatment, four-period crossover pilot study was completed in healthy male and non-pregnant female subjects. Twenty (20) healthy subjects were enrolled. Twenty-one (20) subjects completed the study and had evaluable data throughout the entire study period.

[0245] Endpoints The primary study endpoints were to ascertain the pharmacokinetics of three different doses (1.2 mg, 1.6 mg, and 3 mg) of naltrexone hydrochloride nasal sprays (Test Products 1, 2, and 3, also referred to herein as T1, T2, and T3, respectively) compared to a 50 mg oral dose of naltrexone hydrochloride (reference product, also referred to herein as R) and to identify an intranasal dose of test product that could achieve a naltrexone systemic exposure comparable to the 50 mg oral dose. Secondary study endpoints were to assess the safety and tolerability of the test products, particularly nasal irritation symptoms (e.g., erythema, edema, and erosion).

[0246] Inclusion and Exclusion Criteria The inclusion criteria for this study were as follows: written informed consent; Male or female subjects aged 18–55 years (inclusive) at the time of consent; Weight ≥ 48 kg and body mass index (BMI) 18.0–30.0 kg / m 2 (inclusive) Resting systolic blood pressure 90-1140mmHg (inclusive), and diastolic blood pressure 65-90 (inclusive); Resting heart rate between 40 and 100 bpm (inclusive); Resting respiratory rate 8-120 (inclusive); have adequate venous access; No clinically significant abnormalities on physical examination; Absence of clinically significant abnormalities on a 12-lead ECG recorded at least 3 minutes after the patient was placed in a supine position; absence of clinically significant abnormalities in hematology, biochemistry, coagulation, and urinalysis parameters; Test results must be negative for anti-HIV-1Ab and anti-HIV-2Ab antibodies, hepatitis B surface antigen (HBsAg), and anti-hepatitis C virus antibody (anti-HCVAb); being a non-smoker or ex-smoker (i.e., someone who had abstained from tobacco-containing or nicotine-containing products within the previous 3 months); (Occasional use of tobacco-containing or nicotine-containing products is acceptable if nicotine addiction is not present and subjects agree to abstain from smoking for the duration of the study); Willingness to accept and comply with study restrictions (e.g., alcohol consumption, methylxanthines, diet, exercise, contraception, and medications); and If female, infertile, postmenopausal, or of childbearing potential, agreed to use effective non-hormonal or hormonal contraception for at least 4 weeks from admission through Period 1, and continued a stable continuous regimen through the end of the study to ensure stable plasma hormone levels throughout the entire study period. It was.

[0247] Exclusion criteria at screening were: Known hypersensitivity / allergic reactions to the study drug substance or any excipients; Known severe hypersensitivity reactions to any other drug; Any nasal condition, including abnormal nasal anatomy, nasal symptoms (i.e., nasal congestion and / or runny nose, nasal polyps, etc.), rhinitis, and other conditions known to affect nasal absorption, or the product may have been sprayed into the nasal cavity prior to drug administration; previous or current opioid dependence, alcohol dependence, or other drug dependence (excluding nicotine and caffeine) based on medical history; Concomitant illnesses that were deemed clinically significant by the investigator with respect to the study aspect; the need for concomitant treatment medication during the study; Any medical condition (e.g., gastrointestinal, including gastrointestinal, renal, or hepatic ulcer, inflammatory bowel disease, or pancreatitis) or surgical condition (e.g., cholecystectomy, gastrectomy) that may affect pharmacokinetics (absorption, distribution, metabolism, or excretion) or subject safety; current or recent (within 7 days prior to screening) upper respiratory tract infection; QTc interval ≥450 msec for men and >470 msec for women; a positive drug of abuse urine test or ethanol breath test result; use of any drug depot injection or implant (except contraceptives) within the previous 3 months; Within the previous 6 months, on average, >14 units of alcohol (12 grams / unit) for men and >7 units for women were consumed weekly; On average, methylxanthine-containing beverages or foods (e.g., coffee, tea, cola, soda, chocolate) equivalent to >500 mg methylxanthine were consumed daily (100 mg methylxanthine is equivalent to approximately 150 mL of coffee, 300 mL of tea, 75 mL of hot chocolate, 800 mL of cola, 300 mL of energy drink, or a 25 g chocolate bar); Participation in any clinical trial within the previous two months or participation in more than two clinical trials within the previous 12 months; having donated blood or lost a large amount of blood (≥450 mL) for any reason or undergone plasmapheresis within the previous 2 months; have any dietary restrictions that may make fasting difficult or interfere with the meals provided during the study, e.g. lactose intolerance, vegan, low-fat, low-sodium, etc.; Difficulty donating blood in either arm; Difficulty swallowing capsules or tablets; If female, pregnant or breastfeeding women; and Any other condition that makes the subject unsuitable for the study, as deemed by the Investigator It was.

[0248] Exclusion criteria at the time of admission were: Resting systolic blood pressure 90-140mmHg (inclusive), and diastolic blood pressure 65-90 (inclusive); Resting heart rate between 40 and 100 bpm (inclusive); Resting respiratory rate 8-20 (inclusive); QTcF interval>500msec; significant arrhythmias defined as supraventricular tachycardia of six or more beats or ventricular tachycardia of three or more beats; any recent illness or condition or procedure that occurred during the time period in which study participation would, according to the Investigator, place the subject at undue risk or that may interfere with the pharmacokinetics of the study drug; use of prescription or non-prescription medicinal products, including vitamins, dietary supplements, and herbal supplements (including St. John's wort), within the previous 14 days, unless in the opinion of the investigator the medication would not interfere with the pharmacokinetics of the study drug or compromise the subject's safety (use of topical products not absorbed systemically or recommended contraceptives was permitted); Consumption of any alcoholic products within the previous 72 hours; a positive drug of abuse urine test or ethanol breath test result; If a woman of childbearing potential, a positive urine β-hCG pregnancy test; and Any other condition that makes the subject unsuitable for the study period, as deemed by the Investigator It was.

[0249] Clinical Procedure Subjects were housed in a clinical research facility for 15 nights during the study. Each subject underwent four treatment periods during the study. Each subject received one of four treatments in each of the four treatment periods.

[0250] (Table 8) TIFF2024164155000017.tif72162

[0251] According to the randomization plan, subjects were assigned to one of several treatment sequences in which the investigational products T1, T2, T3, and R were administered in various orders. The investigational products were administered in the morning after an overnight fast of at least 10 hours. The reference product was administered orally (swallowed) as a single dose with 240 mL of water. Two doses of each test product were administered. With the subject in an upright position, the first dose was administered into one nostril and 2 hours later the second dose was administered into the other nostril. Subjects were instructed to hold their breath during the scheduled administration of the nasal spray into the nostril. The test products were primed before use. After priming, the dosing device was weighed before and after each administration to determine the weight of the dose administered. Dosing of each investigational product was separated by a washout interval of 3 days.

[0252] During each study period, subjects who had fasted overnight remained fasting until breakfast, which was served approximately 3 hours after dosing with the reference product and 1 hour after the second dose of test product. No liquids were permitted from 1 hour before dosing until 3 hours after dosing (time point defined for the first dose of test product or the reference product). Water was available ad libitum at all other times. Identical standardized meals and snacks were provided during all periods. Lunch was served approximately 3 hours after breakfast, and all other meals were scheduled at appropriate times by the clinical site.

[0253] Sample collection and analysis To determine plasma concentrations of naltrexone and 6β-naltrexol during each study period, 24 venous blood samples (4 mL volume each) were collected at the following time points: pre-dose and after dosing of the reference product and the first dose of the test product, at 0:02, 0:05, 0:10, 0:15, 0:20, 0:30, 0:45, 1:00, 2:00, 2:05, 2:10, 2:15, 2:20, 2:30, 2:45, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 24:00, and 48:00 hours:minutes.

[0254] Plasma concentrations of naltrexone and 6β-naltrexol were measured using a previously validated liquid chromatography-tandem mass spectrometry (LC-MS / MS) analytical method.

[0255] Pharmacokinetic parameters of naltrexone and 6β-naltrexol were estimated using noncompartmental methods and the ln-linear terminal phase assumption using Phoenix® WinNonlin® version 8.1 (Certara USA Inc, Princeton, NJ) or later. Actual times of blood sampling were used to estimate pharmacokinetic parameters.

[0256] The following pharmacokinetic parameters: The maximum observed plasma concentration (C max ); C max Time of occurrence (T max ); The area under the plasma concentration versus time curve (AUC) from pre-dose (time 0) to the last sampling time with a quantifiable concentration (AUC 0-t ); AUC from time 0 to infinity (AUC 0-∞ ); Apparent terminal elimination rate constant (λ z ); Apparent terminal elimination half-life (t 1 / 2 ; but it should be noted that one value is given here for each of the two doses; and Apparent total clearance of a drug from plasma (CL / F) The C of naltrexone and 6β-naltrexol was estimated. max , T max , AUC 0-t , and AUC 0-∞ was the primary endpoint.

[0257] Using a mixed effects model, the ln transformation C max , AUC 0-t , and AUC 0-∞ Analysis of variance (ANOVA) was performed to compare the results. Sequence, period, and treatment were included as independent factors in the ANOVA model. max , AUC 0-t , and AUC 0-∞ The test-to-reference geometric least squares mean ratio (GMR) and corresponding 90% confidence intervals (CI) were calculated for each. The relative extent of intranasal absorption (Frel) (test vs. reference) was calculated as the dose-adjusted AUC 0-t The nonparametric test was used to estimate the max The secondary endpoint was λ z , t 1 / 2 , and CL / F.

[0258] safety Safety was assessed by evaluating adverse events, 12-lead ECG, vital signs, nasal examination, weight measurement, olfactory examination, and clinical examination (see flow chart). Adverse events were monitored throughout the study.

[0259] result The results are shown below and in the accompanying figures.

[0260] Table 9 shows the means of the naltrexone primary pharmacokinetic parameters of twenty (20) subjects following administration of Test Product 1, Test Product 2, Test Product 3, and the Reference Product, along with their respective summary statistics.

[0261] (Table 9) TIFF2024164155000018.tif210126

[0262] Table 10 shows the means of the naltrexone secondary pharmacokinetic parameters of twenty (20) subjects following administration of Test Product 1, Test Product 2, Test Product 3, and the Reference Product, along with their respective summary statistics.

[0263] (Table 10) TIFF2024164155000019.tif241141

[0264] Table 11 shows the mean naltrexone pharmacokinetic parameters of twenty (20) subjects after the first and second doses of Test Product 1, Test Product 2, Test Product 3, and Reference Product, along with their respective summary statistics.

[0265] (Table 11) TIFF2024164155000020.tif185136

[0266] Table 12 shows the means of the 6β-naltrexol primary pharmacokinetic parameters for twenty (20) subjects following administration of Test Product 1, Test Product 2, Test Product 3, and the Reference Product, along with their respective summary statistics.

[0267] (Table 12) TIFF2024164155000021.tif208130

[0268] Table 13 shows the means of 6β-naltrexol secondary pharmacokinetic parameters and respective summary statistics for twenty (20) subjects following administration of Test Product 1, Test Product 2, Test Product 3, and the Reference Product.

[0269] (Table 13) TIFF2024164155000022.tif241141

[0270] Naltrexone ln conversion C max , AUC 0-t , and AUC 0-∞ To compare the variance, an analysis of variance (ANOVA) was performed using a mixed-effects model according to the protocol. Test-to-reference geometric least squares mean ratios (GMRs) and corresponding 90% confidence intervals (CIs) were calculated. The results of the comparison of the three different test products (Test Product 1, Test Product 2, and Test Product 3) with the reference are summarized in Table 14.

[0271] Table 14. Mixed-effects ANOVA results for naltrexone pharmacokinetic parameters TIFF2024164155000023.tif127162 1 LS average value is C max is expressed in ng / mL and AUC is expressed in ng.h / mL.

[0272] 6β-Naltrexol ln conversion C max , AUC 0-t , and AUC 0-∞ To compare the variances, an analysis of variance (ANOVA) was performed using a mixed-effects model according to the protocol. Test-to-reference geometric least squares mean ratios (GMRs) and corresponding 90% confidence intervals (CIs) were calculated. The results of the comparison of the three different test products (Test Product 1, Test Product 2, and Test Product 3) with the reference are summarized in Table 15.

[0273] Table 15. Mixed-effects ANOVA results for naltrexone pharmacokinetic parameters TIFF2024164155000024.tif128162 1LS mean values ​​were expressed in ng / mL for Cmax and in ng.h / mL for AUC.

[0274] According to the protocol, the relative extent of intranasal absorption of naltrexone (F rel ) (test vs. reference) as the dose-adjusted AUC 0-t (AUC 0-t / D ). Table 16 shows the arithmetic means and coefficients of variation (CV%) of the estimated parameters.

[0275] Table 16: Naltrexone - Relative extent of intranasal absorption TIFF2024164155000025.tif41162n - Number of objects AUC 0-t / D-dose normalized AUC0-t. For each test product, D corresponds to the total administered dose of the product. F rel -Relative degree of intranasal absorption (test / reference)

[0276] According to the protocol, the tmax obtained for each formulation was compared using non-parametric tests as shown in Table 17.

[0277] Table 17 Naltrexone: max Nonparametric analysis TIFF2024164155000026.tif34162

[0278] Other Aspects The detailed description given herein is provided to help those skilled in the art to practice the present disclosure. However, the disclosure described and claimed herein should not be limited in scope by the specific embodiments disclosed herein, since these embodiments are intended as illustrations of some aspects of the present disclosure. Any equivalent embodiments are intended to be within the scope of the present disclosure. Indeed, various modifications of the present disclosure in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description, which do not depart from the spirit or scope of the discovery of the present invention. Such modifications are also intended to be within the scope of the appended claims.

[0279] All U.S. or foreign references, patents, or applications cited in this application are hereby incorporated by reference as if fully set forth herein. In the event of a conflict, the material literally disclosed herein will control.

[0280] Although the invention has been described with reference to the above examples, it is understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the scope of the following claims.

Claims

1. An aqueous solution comprising about 1 mg to about 4 mg of naltrexone or a pharma- ceutically acceptable salt thereof.

13. An intranasal formulation comprising:

2. An aqueous solution comprising about 10 mg / mL to about 40 mg / mL of naltrexone or a pharma- ceutically acceptable salt thereof. in a volume of about 50 to about 150 μL.

3. below: Isotonic agents; Preservatives; Stabilizers; Absorption enhancers; and A sufficient amount of water to achieve a final volume of about 50 to about 150 μL 3. The formulation of claim 1 or claim 2, further comprising:

4. below: about 1 mg to about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof; about 0.1 mg to about 1.2 mg of an isotonic agent; from about 0.001 mg to about 0.1 mg of a preservative; about 0.1 mg to about 0.5 mg of a stabilizer; about 0.05 mg to about 2.5 mg of an absorption enhancer; and A sufficient amount of water to achieve a final volume of about 50 to about 150 μL 4. The formulation of claim 3, comprising:

5. below: about 1% to about 3% naltrexone or a pharma- ceutically acceptable salt thereof; about 0.1% to about 1.2% isotonic agent; from about 0.001% to about 0.1% preservative; about 0.1% to about 0.5% of a stabilizer; About 0.05% mg to about 2.5% absorption enhancer 4. The formulation of claim 3, comprising:

6. The isotonic agent is NaCl, The preservative is benzalkonium chloride. The stabilizer is edetate disodium, The absorption enhancer is an alkyl saccharide; 6. The formulation of claim 4 or claim 5.

7. 7. The formulation of claim 6, wherein the alkyl saccharide is dodecyl maltoside.

8. below: about 1 mg to about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof; about 0.1 mg to about 1.2 mg NaCl; about 0.001 mg to about 0.1 mg of benzalkonium chloride; about 0.15 mg to about 0.5 mg of edetate disodium; about 0.05 mg to about 2.5 mg of dodecyl maltoside; and A sufficient amount of water to achieve a final volume of about 50 to about 150 μL 8. The formulation of claim 7, comprising:

9. 9. The formulation of claim 8, comprising about 0.1 mg to about 0.5 mg of dodecyl maltoside.

10. 10. The formulation of claim 9, comprising about 0.25 mg of dodecyl maltoside.

11. 9. The formulation of claim 8, comprising about 0.2 mg and about 0.3 mg of edetate disodium.

12. below: about 1 mg to about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof; about 0.3 mg to about 0.7 mg NaCl; Approximately 0.02 mg of benzalkonium chloride; Approximately 0.3 mg of edetate disodium; Approximately 0.25 mg of dodecyl maltoside; and A sufficient amount of water to achieve a final volume of about 50 to about 150 μL 10. The formulation of claim 9, comprising:

13. 11. The formulation of claim 10, wherein the amount of water is sufficient to achieve a final volume of about 80 to about 120 μL.

14. 12. The formulation of claim 11, wherein the amount of water is sufficient to achieve a final volume of about 100 μL.

15. below: about 1% to about 3% naltrexone or a pharma- ceutically acceptable salt thereof; about 0.1% to about 1.2% NaCl; about 0.001% to about 0.1% benzalkonium chloride; about 0.15% to about 0.5% edetate disodium; about 0.05% to about 2.5% dodecyl maltoside; and water 8. The formulation of claim 7, comprising:

16. 16. The formulation of claim 15, comprising about 0.1% to about 0.5% dodecyl maltoside.

17. 17. The formulation of claim 16, comprising about 0.25% dodecyl maltoside.

18. 16. The formulation of claim 15, comprising about 0.2% and about 0.3% edetate disodium.

19. below: about 1% to about 3% naltrexone or a pharma- ceutically acceptable salt thereof; about 0.3% to about 0.7% NaCl; Approximately 0.02% benzalkonium chloride; Approximately 0.3% disodium edetate; Approximately 0.25% dodecyl maltoside; and water 20. The formulation of claim 17, comprising:

20. 20. The formulation of claim 19, wherein the amount of water is sufficient to achieve a final volume of about 50 to about 150 μL.

21. 21. The formulation of claim 20, wherein the amount of water is sufficient to achieve a final volume of about 100 μL.

22. 22. The formulation of any one of claims 1 to 21, wherein the naltrexone is naltrexone hydrochloride.

23. 23. The formulation of claim 22, comprising about 1.2 mg, about 1.6 mg, about 2.0 mg, or about 3.0 mg of naltrexone or an equivalent amount of naltrexone hydrochloride.

24. 1. A method of treating an opioid overdose or a reward-based disorder in a subject, comprising: An aqueous solution comprising about 1 mg to about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof. administering to a subject an intranasal formulation comprising A method comprising:

25. 1. A method of treating an opioid overdose or a reward-based disorder in a subject, comprising: An aqueous solution comprising about 1 mg to about 4 mg of naltrexone or a pharma- ceutically acceptable salt thereof. administering to the subject a first intranasal formulation comprising: An aqueous solution comprising about 1 mg to about 4 mg of naltrexone or a pharma- ceutically acceptable salt thereof. administering a second intranasal formulation comprising A method comprising:

26. 1. A method of treating an opioid overdose or a reward-based disorder in a subject, comprising: An aqueous solution comprising about 10 mg / mL to about 30 mg / mL of naltrexone or a pharma- ceutically acceptable salt thereof. in a volume of about 50 to about 150 μL. A method comprising:

27. 1. A method of treating an opioid overdose or a reward-based disorder in a subject, comprising: An aqueous solution comprising about 10 mg / mL to about 40 mg / mL of naltrexone or a pharma- ceutically acceptable salt thereof. administering to the subject a first intranasal formulation comprising in a volume of about 50 to about 250 ul; and An aqueous solution comprising about 10 mg / mL to about 40 mg / mL of naltrexone or a pharma- ceutically acceptable salt thereof. in a volume of about 50 to about 250 μL. A method comprising:

28. 28. The method of claim 25 or claim 27, wherein the second intranasal formulation is administered about 1 hour to about 3 hours after the first intranasal formulation.

29. Intranasal formulations include: Isotonic agents; Preservatives; Stabilizers; Absorption enhancers; and A sufficient amount of water to achieve a final volume of about 50 to about 150 μL The method of any one of claims 24 to 28, further comprising:

30. The intranasal formulation about 1 mg to about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof; about 0.1 mg to about 1.2 mg of an isotonic agent; from about 0.001 mg to about 0.1 mg of a preservative; about 0.1 mg to about 0.5 mg of a stabilizer; about 0.05 mg to about 2.5 mg of an absorption enhancer; and A sufficient amount of water to achieve a final volume of about 50 to about 150 μL 30. The method of claim 29, comprising:

31. Intranasal formulations include: about 1% to about 3% naltrexone or a pharma- ceutically acceptable salt thereof; about 0.1% to about 1.2% isotonic agent; from about 0.001% to about 0.1% preservative; about 0.1% to about 0.5% of a stabilizer; About 0.05% mg to about 2.5% absorption enhancer 30. The method of claim 29, comprising:

32. The isotonic agent is NaCl, The preservative is benzalkonium chloride. The stabilizer is edetate disodium, The absorption enhancer is an alkyl saccharide; 32. The method of claim 30 or claim 31.

33. 33. The method of claim 32, wherein the alkyl saccharide is dodecyl maltoside.

34. Intranasal formulations include: about 1 mg to about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof; about 0.1 mg to about 1.2 mg NaCl; about 0.001 mg to about 0.1 mg of benzalkonium chloride; about 0.15 mg to about 0.5 mg of edetate disodium; about 0.05 mg to about 2.5 mg of dodecyl maltoside; and A sufficient amount of water to achieve a final volume of about 50 to about 150 μL 34. The method of claim 33, comprising:

35. 35. The method of claim 34, wherein the intranasal formulation comprises about 0.1 mg to about 0.5 mg of dodecyl maltoside.

36. 36. The method of claim 35, wherein the intranasal formulation comprises about 0.25 mg of dodecyl maltoside.

37. 35. The method of claim 34, wherein the intranasal formulation comprises about 0.2 mg to about 0.3 mg of edetate disodium.

38. The intranasal formulation about 1 mg to about 3 mg of naltrexone or a pharma- ceutically acceptable salt thereof; about 0.3 mg to about 0.7 mg NaCl; Approximately 0.02 mg of benzalkonium chloride; Approximately 0.3 mg of edetate disodium; Approximately 0.25 mg of dodecyl maltoside; and A sufficient amount of water to achieve a final volume of about 50 to about 150 μL 37. The method of claim 36, comprising:

39. 40. The method of claim 38, wherein the amount of water is sufficient to achieve a final volume of about 50 to about 150 μL.

40. 40. The method of claim 39, wherein the amount of water is sufficient to achieve a final volume of about 100 μL.

41. below: about 1% to about 3% naltrexone or a pharma- ceutically acceptable salt thereof; about 0.1% to about 1.2% NaCl; about 0.001% to about 0.1% benzalkonium chloride; about 0.1% to about 0.5% edetate disodium; about 0.05% to about 2.5% dodecyl maltoside; and water 34. The method of claim 33, comprising:

42. 42. The method of claim 41, wherein the intranasal formulation comprises about 0.1% to about 0.5% dodecyl maltoside.

43. 43. The method of claim 42, wherein the intranasal formulation comprises about 0.25% dodecyl maltoside.

44. 42. The method of claim 41, wherein the intranasal formulation comprises about 0.2% to about 0.3% edetate disodium.

45. Intranasal formulations include: about 1% to about 3% naltrexone or a pharma- ceutically acceptable salt thereof; about 0.3% to about 0.7% NaCl; Approximately 0.02% benzalkonium chloride; Approximately 0.3% disodium edetate; Approximately 0.25% dodecyl maltoside; and water 44. The method of claim 43, comprising:

46. 46. ​​The method of claim 45, wherein the amount of water is sufficient to achieve a final volume of about 50 to about 150 μL.

47. 47. The method of claim 46, wherein the amount of water is sufficient to achieve a final volume of about 100 μL.

48. The method of any one of claims 24 to 47, wherein the naltrexone is naltrexone hydrochloride.

49. 49. The method of claim 48, wherein the intranasal formulation comprises about 1.2 mg, about 1.6 mg, about 2.0 mg, or about 3.0 mg of naltrexone or an equivalent amount of naltrexone hydrochloride.

50. The method of any one of claims 24 to 49, for treating opioid overdose.

51. 50. The method of any one of claims 24 to 49, wherein the method treats a reward-based disorder.

52. 49. The method of claim 48, wherein the reward-based disorder is a substance use disorder.

53. 49. The method of claim 48, wherein the substance use disorder is alcohol use disorder.

54. 54. The method of claim 53, wherein the intranasal formulation comprising naltrexone is administered prior to alcohol consumption.

55. 55. The method of claim 54, wherein the intranasal formulation comprising naltrexone is administered about 1 to 2 hours prior to alcohol consumption.

56. 55. The method of claim 54, wherein the intranasal formulation comprising naltrexone is administered about 0.5 to about 1 hour prior to alcohol consumption.

57. 55. The method of claim 54, wherein the intranasal formulation comprising naltrexone is administered about 10 to about 30 minutes prior to alcohol consumption.

58. 55. The method of claim 54, wherein the intranasal formulation comprising naltrexone is administered about 5 to about 10 minutes prior to alcohol consumption.

59. 54. The method of claim 53, wherein the intranasal formulation comprising naltrexone is administered simultaneously with alcohol intake.

60. 54. The method of claim 53, wherein the intranasal formulation comprising naltrexone is administered within 0.5 hours after the start of alcohol ingestion.

61. 61. The method of any one of claims 24-60, wherein the intranasal formulation comprising naltrexone is administered to the subject from 1 to 4 times daily.

62. 62. The method of claim 61, wherein the intranasal formulation comprising naltrexone is administered at a dose of about 1.2 mg, about 1.6 mg, about 2 mg, or about 3 mg throughout the day as needed by the subject.

63. 36. The method of claim 35, wherein the intranasal formulation comprising naltrexone is administered as a first dose of about 1.2 mg, about 1.6 mg, about 2 mg, or about 3 mg in the morning and as a subsequent dose of about 1.2 mg, about 1.6 mg, about 2 mg, or about 3 mg as needed prior to alcohol consumption.

64. 24. A method for administering a nasal composition comprising administering to a patient a plurality of doses comprising administering to said ... A multi-dose device adapted for nasal delivery of pharmaceutical formulations to subjects experiencing an opioid overdose or having a reward-based disorder.

65. The device of any one of claims 59-64, wherein each dose delivers about 0.05 to about 0.15 mL of the formulation to the subject.

66. 66. The device of claim 65, wherein each dose delivers about 0.1 mL of the formulation to the subject.

Citation Information

Patent Citations

  • Compositions for drug administration

    JP2012513412A

  • Nasal drug product and method of use

    JP2017508800A

  • Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same

    US20070212307A1

  • Intranasal naltrexone

    US20170020862A1

  • Compositions, devices, and methods for the treatment of alcohol use disorder

    WO2017223566A1